header logo image


Page 4«..3456..1020..»

Archive for April, 2020

Precision BioSciences Announces Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting – BioSpace

Wednesday, April 29th, 2020

DURHAM, N.C., April 28, 2020 (GLOBE NEWSWIRE) -- Precision BioSciencesInc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS gene editing platform, today announced that the Company and its collaborators will present at the upcoming American Society of Genetic & Cell Therapy (ASGCT) Annual Meeting held virtually May 12-15, 2020.

The abstracts being presented by Precision and our collaborators this year at ASGCT underscore the differentiated capabilities of our proprietary ARCUS genome editing platform and the breadth of our emerging pipeline applying this technology in vivo, commented Derek Jantz, Chief Scientific Officer and co-founder of Precision BioSciences. These presentations demonstrate the specificity and versatility of ARCUS-driven genome editing in a variety of large animal models and provide further preclinical evidence of potentially meaningful and durable therapeutic impact on a range of genetic and infectious diseases. As we continue to validate ARCUS potential in vivo, we are focused on advancing our gene correction pipeline. We look forward to selecting a clinical candidate for our wholly owned PH1 program, expected in 2020, and, in partnership with Gilead, developing a potential cure for chronic hepatitis B infection, for which submission of an IND is currently targeted for 2021.

Precision BioSciences Presentations:

Title:Engineering a Self-Inactivating Adeno-Associated Virus (AAV) Vector for ARCUS Nuclease DeliveryPoster Session: Gene Targeting and Gene Correction, Abstract: 654Presenting Author: Hui Li, Ph.D., Precision BioSciences

Title:A Gene Editing Approach to Eliminate Hepatitis B Virus Using ARCUS MeganucleasesPoster Session: Gene Targeting and Gene Correction, Abstract 1057Presenting Author: Cassie Gorsuch, Ph.D., Precision BioSciences

Partnered Presentations:

Title: Therapeutic Efficacy of ARCUS Meganuclease Gene Editing - Arrest of Rod Degeneration and Restoration of Rod Function in a Transgenic Pig Model of Autosomal Dominant Retinitis PigmentosaOral Presentation: Gene Therapy for the Special Senses, Abstract 2Date/Time: Tuesday, May 12, 2020, 10:30 10:45 a.m. ESTPresenting Author: Maureen Ann McCall, Ph.D., Professor, Department of Ophthalmology and Visual Sciences, University of Louisville

Title: Evaluation of the Long-term Effects of AAV-Meganuclease Genome Editing of PCSK9 in Macaque LiverOral Presentation: Evaluating Genome Editing Activity and Precision, Abstract 518Date/Time: Wednesday, May 13, 2020, 4:00 4:15 p.m. ESTPresenting Author: Lili Wang, Ph.D., Research Director, Discovery Research and Gene Editing, Research Associate Professor, Department of Medicine, Perelman School of Medicine, University of Pennsylvania

All abstracts for the ASGCT 2020 Meeting are available online at ASGCT Annual Meeting Abstracts.

About Precision BioSciences, Inc.Precision BioSciences is dedicated to improving life (DTIL) through its proprietary genome editing platform, ARCUS. Precision leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and create healthy and sustainable food and agriculture solutions. Precision is actively developing product candidates in three innovative areas: allogeneic CAR T immunotherapy, in vivo gene correction, and food. For more information regarding Precision, please visitwww.precisionbiosciences.com.

Forward-LookingStatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including the timing of trials and results from clinical and non-clinical studies of our in vivo gene correction program and the safety, efficacy and delivery of our ARCUS genome editing technology. In some cases, you can identify forward-looking statements by terms such as anticipate, believe, could, expect, should, plan, intend, estimate, target, mission, may, will, would, should, could, target, project, predict, contemplate, potential, or the negative thereof and similar words and expressions.

Forward-looking statements are based on managements current expectations, beliefs and assumptions and on information currently available to us. Such statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, our ability to become profitable; our ability to procure sufficient funding and requirements under our current debt instruments; our limited operating history; the success of our programs and product candidates; our dependence on our ARCUS technology; the initiation, cost, timing, progress and results of research and development activities, preclinical or greenhouse studies and clinical or field trials; our or our collaborators ability to identify, develop and commercialize product candidates; our or our collaborators ability to advance product candidates into, and successfully complete, clinical or field trials; our or our collaborators ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; the laws and regulatory landscape that will apply to our and our collaborators development of product candidates; our ability to achieve our anticipated operating efficiencies as we commence manufacturing operations at our new facility; delays or difficulties in enrolling patients in clinical trials; our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates; potential litigation relating to infringement or misappropriate of intellectual property rights; if our product candidates do not work as intended or cause undesirable side effects the potential for off-target editing or other adverse events, undesirable side effects or unexpected characteristics associated with any of our product candidates; risks associated with applicable healthcare, data privacy and security regulations and our compliance therewith; the rate and degree of market acceptance of any of our product candidates; the success of our existing collaboration agreements; our ability to enter into new collaboration arrangements; public perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, biotechnology and agricultural biotechnology fields; potential manufacturing problems associated with any of our product candidates; pending and potential liability lawsuits and penalties related to our technology, our product candidates; the outbreak of the novel coronavirus disease (COVID-19); our current and future relationships with third parties; our ability to effectively manage the growth of our operations; our ability to attract, retain, and motivate key scientific and management personnel; effects of natural or manmade disasters, public health emergencies and other natural catastrophic events; insurance expenses and exposure to uninsured liabilities; market and economic conditions; dilution and fluctuations in our stock price; and other important factors discussed under the caption Risk Factors in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as supplemented by the risk factor contained in our Current Report on Form 8-K filed with the SEC on April 6, 2020, as any such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SECs website atwww.sec.gov.

All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Investor Contacts:Nick RiddlePrecision BioSciencesTel. (919) 314-5512IR@precisionbiosciences.com

Josh RappaportStern Investor RelationsTel. (212) 362-1200josh.rappaport@sternir.com

Media Contact:Maurissa MessierPrecision BioSciencesTel. (919) 314-5512media@precisionbiosciences.com

See original here:
Precision BioSciences Announces Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting - BioSpace

Read More...

4THBIN Appoints Cynthia Salitsky as Chief Marketing Officer to Support Market Expansion and Drive Growth – PRNewswire

Wednesday, April 29th, 2020

Ms. Salitsky joins 4THBIN from The Chemours Company, where she held the role of Global Communications Director for Chemours' Fluoroproducts business and led crisis and issues communications for the company. During her tenure at Chemours, she was responsible for developing the company's strategic brand and marketing agenda for six of the company's seven power brands. Prior to joining Chemours, Ms. Salitsky spent twenty years with AstraZeneca, where she held numerous communication leadership roles, including Head of Enablement for Global R&D Communications,Head of Key Account Management and Communication Excellence, Global R&D and Director, R&D PR-Communication Strategy.Ms. Salitsky holds a Bachelor of Science degree in Genetic Engineering from Cedar Crest College and completed the Wharton Management Program at the University of Pennsylvania.

With over 25 years of experience, Ms. Salitsky has a unique blend of expertise in communications, sales and marketing, strategic planning as well as managerial and operational excellence. Her career is marked with critical roles in several 'start up' functions and capabilities within an organization, making her a perfect fit for 4THBIN.

"We are delighted to have someone of Cynthia's caliber and experience join our team," said Paul Kirsch, CEO and Co-founder of 4THBIN. "4THBIN has experienced exponential growth over the past couple of years, and Cynthia's experience will help us continue to expand our market reach and drive future growth."

"I couldn't be more excited to join such an amazing team that is truly passionate about making a difference and executing on its promise to deliver sustainable and secure e-recycling and data destruction solutions to today's leading industries," said Salitsky.

About 4THBIN

4THBIN is a certified and secure e-recycling solution provider to over 6,000 businesses from Fortune 100 companies to start-ups across the United States.We provide certified data destruction support to today's top industries and help them deliver on their corporate social responsibility commitments by ensuring their e-waste is sustainably and legally recycled. We are certified and accredited by the industry's most rigorous and trusted institutions for data security and sustainability.4THBIN was New York City's first company to be certified by e-Stewards and has received Evovadis' platinum rating, placing 4TBIN in the top 1% of their most responsible companies. For more information, we invite you to visit 4THBIN.comor follow ups on Twitter @4THBINor LinkedIN.

Media Contact:Kira Perdue[emailprotected]404-556-0062

SOURCE 4THBIN

http://www.4THBIN.com

Visit link:
4THBIN Appoints Cynthia Salitsky as Chief Marketing Officer to Support Market Expansion and Drive Growth - PRNewswire

Read More...

The US already has the technology to test millions of people a day – MIT Technology Review

Wednesday, April 29th, 2020

There is widespread agreement that the only way to safely reopen the economy is through a massive increase in testing. The US needs to test millions of people per day to effectively track and then contain the covid-19 pandemic.

This is a tall order. The country tested only around 210,000 people per day last week, and the pace is not increasing fast enough to get to millions quickly.

The urgency to do better is overwhelmingly bipartisan, with the most recent legislation adding $25 billion for testing a few days ago. Fears are growing, however, that testing might not scale in time to make a difference. As Senators Lamar Alexander and Roy Blunt wrote last week, We have been talking with experts across the government and the private sector to find anyone who believes that current technology can produce the tens of millions of tests necessary to put this virus behind us. Unfortunately, we have yet to find anyone to do so.

We believe that it can be done. The scientific community has the technological capabilities today to test everyone who needs it and enable people to come back to work safely.

To be clearthe senators are right that simply scaling up current practices for covid testing is insufficient. However, with a bit of innovation, the US can meet the need without inventing entirely new technologies. The necessary scale can be achieved by deploying the fruits of the last decade of innovation in biology, including the dizzying advances in DNA sequencing, genetic engineering, industrial automation, and advanced computation.

We speak from experience. We have worked with and helped engender many of these technologies across academia and industry. Scaling them for widespread testing will require investment, infrastructure, and determination, but nothing technologically or logistically infeasible.

Tests for mass screening may have different requirements and characteristics from the tests run in clinical labs today that are approved by the Food and Drug Administration. So what might a solution look like?

It must be scalable, meaning tens or hundreds of thousands of tests per day per facility, or at-home tests. It must be sensitive to early stages of infection, detecting the actual virus rather than immunity to it. And it must be less bound by health insurance and regulatory constraints, to allow fast and broad testing, contact tracing, and isolation. These differences do not mean lower standards. In fact, screening at this scale will require stringent requirements for safety, accuracy, and reliability.

The life sciences community is rising to the challenge. We are repurposing our labs to advance new centralized and at-home methods that solve the bottlenecks preventing testing from reaching global scale. This community is moving fast, with shared purpose and a commitment to open collaboration. As a result of these efforts, several promising avenues are emerging.

Some rely on DNA sequencing tools that have improved a million-fold since the completion of the Human Genome Project nearly 20 years ago. Not only can these tools now read trillions of base pairs of human DNA every day, but they can be readily repurposed to test for the presence of coronavirus at mass scale, using instruments that already exist across the country. Some methods, such as SHERLOCK and DETECTR, harness CRISPR DNA and RNA recognition tools to enable rapid, distributed testing in doctors offices and at other sites. Other efforts are removing critical bottlenecks, such as sample purification, to make the existing approaches more scalable.

There are additional possibilities, and the US needs to place bets on several of them at the same time. Some of those bets might fail, but the severity of the moment requires that we try. Chances are, we will need more than one of them.

As important as the diagnostic technology itself is the need to fuel innovation at all stages of the testing process, including sample collection, regulation, logistics, manufacturing, distribution, scale-up, data infrastructure, and billing. These are solvable problems. The solutions may sometimes differ from current clinical testing conventions, but these are not conventional times.

Maybe cotton swabs or saliva can be used for collection rather than traditional nasopharyngeal swabs, which are in critically short supply. Maybe mass screening tests dont have to have the tested persons name and date on every collection tube but could instead include a bar code that you snap a picture of with your phone. Maybe these tests can be self-administered at home or work rather than conducted by trained professionals in clinical settings. Maybe samples from low-risk, asymptomatic people can be pooled together for initial testing and further screened only in the event of a positive result. This would allow many more samples to be analyzed at once.

State or federal regulatory agencies could make these adjustments to conventional practices more easily if they were willing to treat mass screening for bringing people back to work differently from the testing used in clinical settings. In addition, mass screening efforts will require unconventional partnerships with private companies, nonprofits, universities, and government agencies to support the logistics, collection, manufacturing, scale-up, and data infrastructure to make such a system possible. All this can be done, and some of it is already starting to be donebut we must not lose hope.

The United States capabilities in the life sciences and information technology are unmatched in the world. The time is now to rapidly build a massively scaled screening program that will save lives while allowing us to reopen our economy and keep it open. This can be done, but it will require urgency and determination to make multiple, simultaneous bets on infrastructure, regulation, and technology, as well as collaboration to put it all together.

We have united before to face far greater challenges as a nation, and we can do so again.

Sri Kosuri is cofounder and CEO of Octant and an associate professor in the Department of Chemistry and Biochemistry at UCLA. Feng Zhang is the James and Patricia Poitras Professor of Neuroscience at MITs McGovern Institute, a core member of the Broad Institute, a Howard Hughes Medical Institute Investigator, and cofounder of Sherlock Biosciences. Jason Kelly is cofounder and CEO of Ginkgo Bioworks. Jay Shendure is a Howard Hughes Medical Institute Investigator at the University of Washington School of Medicine and scientific director of the Brotman Baty Institute.

See the original post here:
The US already has the technology to test millions of people a day - MIT Technology Review

Read More...

The Controversial Experiments and Wuhan Lab Suspected of Starting the Coronavirus Pandemic – Newsweek

Wednesday, April 29th, 2020

Just one day after the U.S. surpassed China to become the country with the highest number of Covid-19 cases, the U.S. Defense Intelligence Agency updated its assessment of the origin of the novel coronavirus to reflect that it may have been accidentally released from an infectious diseases lab, Newsweek has learned.

The report, dated March 27 and corroborated by two U.S. officials, reveals that U.S. intelligence revised its January assessment in which it "judged that the outbreak probably occurred naturally" to now include the possibility that the new coronavirus emerged "accidentally" due to "unsafe laboratory practices" in the central Chinese city of Wuhan, where the pathogen was first observed late last year. The classified report, titled "China: Origins of COVID-19 Outbreak Remain Unknown," ruled out that the disease was genetically engineered or released intentionally as a biological weapon.

"We have no credible evidence to indicate SARS-CoV-2 was released intentionally or was created as a biological weapon," the report found. "It is very unlikely that researchers or the Chinese government would intentionally release such a dangerous virus, especially within China, without possessing a known and effective vaccine." Every scientist interviewed by Newsweek for this story also rejected categorically the notion that the virus was intentionally released.

Covid-19 has infected nearly 3 million people across the globe, initially ravaging China before hitting hardest in the West and leaving the United States as the most deeply-afflicted country, with more than 55,000 deaths as of April 27. Its origin remains the subject of not only scientific debate, but a politically charged dispute in the international community.

Citing academic literature, the DIA document states that a "definitive answer may never be known" as to how the disease truly first emerged. A U.S. intelligence spokesperson told Newsweek, "the Intelligence Community has not collectively agreed on any one theory."

Uncertain source

Tracing the origin of a new virus is not easy. It took researchers at the Wuhan Institute more than a decade to trace the 2002-2003 SARS virus to remote bat caves in Yunnan province. It's not surprising, then, that in early February, China's Academy for Military Medical Sciences "concluded that it was impossible for them to scientifically determine whether the Covid-19 outbreak was caused naturally or accidentally from a laboratory incident," according to the DIA document.

Initial assessments conducted by the Chinese government pointed to the city's Huanan Seafood Market as the likely cause of a natural outbreak of SARS-CoV-2, a new coronavirus that causes Covid-19. In the early days of the outbreak, local officials played down the possibility of human-to-human transmission of the virus and silenced doctors who spoke out about the growing outbreak. It may have undercounted deaths and the number of cases of Covid-19. A spurious theory that the U.S. deliberately planted the virus in Wuhan also started circulating.

China's foreign ministry told reporters April 23rd that the World Health Organization found "no evidence" the outbreak started at the Wuhan laboratory, and Yuan Zhiming, vice president of the Wuhan Institute of Virology and president of the Chinese Academy of Sciences Wuhan Branch, blasted the inference of intentional misuse or creation as "malicious" and "impossible."

"The director of the Galveston National Laboratory in the United States made it clear that our laboratory is just as well managed as labs in Europe and the U.S.," he said. "I think it is understandable for people to make that association. But it is a malicious move to purposefully mislead the people" to think that the virus escaped from [our Wuhan] labs.

"They have no evidence or logic to support their accusations. They are basing it completely on their own speculations."

The DIA report, however, cites U.S. government and Chinese researchers that found "about 33 percent of the original 41 identified cases did not have direct exposure" to the market. That, along with what's known of the laboratory's work in past few years, raised reasonable suspicion that the pandemic may have been caused by a lab error, not the wet market.

Here's what the scientific and circumstantial evidence shows.

Back in 2002, when SARS emerged in China's Guandong province, it served as a wake-up call. Over the next few decades, the U.S., China and other nations poured money into efforts to hunt down and catalogue strange new pathogens that live in wild animals and figure out how much of a threat they pose to humans, with the goal of preventing the next devastating pandemic.

In the fall of 2019, the SARS-CoV-2 coronavirus emerged in the middle of the large, cosmopolitan city of Wuhan. Chinese officials at first insisted that the virus, SARS-CoV-2, could be caught only through direct contact with animals. But many of the early patients in Wuhan had no connection to the wild animal markets, which meant that the virus had already been spreading from person to person. When this fact came out, it cast doubt on the veracity of information coming from China, but the virus was well on its way to becoming a deadly pandemic.

In the early days, the prevailing theory of the virus' origins was that it, like SARS, arose in bats, passed to some other mammal such as a pangolin, and ultimately entered the population through the wild-animal markets.

By March, the wild-virus theory was still the most likely explanation of the origin of SARS-CoV-2--but it was starting to look a little ragged around the edges. For one thing, the Wuhan Institute of Virology, not far from the animal markets in downtown Wuhan, houses the world's largest collection of coronaviruses from wild bats, including at least one virus that bears a resemblance to SARS-CoV-2. What's more, Wuhan Institute of Virology scientists have for the past five years been engaged in so-called "gain of function" (GOF) research, which is designed to enhance certain properties of viruses for the purpose of anticipating future pandemics. Gain-of-function techniques have been used to turn viruses into human pathogens capable of causing a global pandemic.

This is no nefarious secret program in an underground military bunker. The Wuhan lab received funding to do this work in part from a ten-year, $200 million international program called PREDICT, funded by the U.S. Agency for International Development and other countries. Similar work, funded in part by the U.S. National Institutes of Health, has been carried out in dozens of labs throughout the world. Some of this research involves taking deadly viruses and enhancing their ability to spread quickly through a populationresearch that took place over the objections of hundreds of scientists, who have warned for years of the program's potential to cause a pandemic.

In the years since the SARS outbreak, many instances of mishaps involving the accidental release of pathogens have taken place in labs throughout the world. Hundreds of breaches have occurred in the U.S., including a 2014 release of anthrax from a U.S. government lab that exposed 84 people. The SARS virus escaped from a Beijing lab in 2004, causing four infections and one death. An accidental release is not complicated and doesn't require malicious intent. All it takes is for a lab worker to get sick, go home for the night, and unwittingly spread the virus to others.

The Wuhan Institute has a record of shoddy practices that could conceivably lead to an accidental release, as officials at the U.S. Embassy in Beijing reportedly warned in a cable on January 19, 2018. "During interactions with scientists at the WIV laboratory, they noted the new lab has a serious shortage of appropriately trained technicians and investigators needed to safely operate this high-containment laboratory," states the cable, according to the Washington Post.

To be sure, there's no evidence that SARS-Cov-2 came from the Wuhan lab, nor that the virus is the product of engineering. Most scientists believe, based on the evidence available, that a natural origin is the most likely explanation. But neither have they ruled out these possibilities. "At this stage, it is not possible to determine precisely the source of the virus which caused the COVID-19 pandemic," says the World Health Organization in a statement to Newsweek. "All available evidence suggests that the virus has a natural animal origin and is not a manipulated or constructed virus."

The circumstantial evidence is strong enough to warrant putting the lab's programs and practices at the heart of the investigation. And it's worth looking anew at whether scientists, in their efforts to protect the public from the threat of natural pathogens, overreached.

Read more

Animal Passage

Ten years ago, the viral pathogen most in the news was not a coronavirus but influenzain particular, a strain of flu, designated H5N1, that arose in birds and killed a high proportion of those who were infected. For a while, the virus made headlines. Then it became clear that nearly everyone who caught the bird-flu virus got it directly from handling birds. To cause a plague, it's not enough that a virus is an efficient killer. It also has to pass easily from one person to the next, a quality called transmissibility.

Around this time, Ron Fouchier, a scientist at Erasmus University in Holland, wondered what it would take for the bird flu virus to mutate into a plague virus. The question was important to the mission of virologists in anticipating human pandemics. If H5N1 were merely one or two steps away from acquiring human transmissibility, the world was in danger: a transmissible form of H5N1 could quickly balloon into a devastating pandemic on the order of the 1918 flu, which killed tens of millions of people.

To answer the question, scientists would have to breed the virus in the lab in cell cultures and see how it mutated. But this kind of work was difficult to carry out and hard to draw conclusions from. How would you know if the end result was transmissible?

The answer that Fouchier came up with was a technique known as "animal passage," in which he mutated the bird-flu virus by passing it through animals rather than cell cultures. He chose ferrets because they were widely known as a good stand-in for humansif a virus can jump between ferrets, it is likely also to be able to jump between humans. He would infect one ferret with a bird-flu virus, wait until it got sick, and then remove a sample of the virus that had replicated in the ferret's body with a swab. As the virus multiplies in the body, it mutates slightly, so the virus that came out of the ferret was slightly different from the one that went into it. Fouchier then proceeded to play a version of telephone: he would take the virus from the first ferret and infect a second, then take the mutated virus from the second ferret and infect a third, and so on.

After passing the virus through 10 ferrets, Fouchier noticed that a ferret in an adjacent cage became ill, even though the two hadn't come into contact with one another. That showed that the virus was transmissible in ferretsand, by implication, in humans. Fouchier had succeeded in creating a potential pandemic virus in his lab.

Read more

When Fouchier submitted his animal-passage work to the journal Science in 2011, biosecurity officials in the Obama White House, worried that the dangerous pathogen could accidentally leak from Fouchier's lab, pushed for a moratorium on the research. Fouchier had done his work in BSL-2 labs, which are intended for pathogens such as staph, of moderate severity, rather than BSL-4, which are intended for Ebola and similar viruses. BSL-4 labs have elaborate safeguardsthey're usually separate buildings with their own air circulation systems, airlocks and so forth. In response, the National Institutes of Health issued a moratorium on the research.

What followed was a fierce debate among scientists over the risks versus benefits of the gain-of-function research. Fouchier's work, wrote Harvard epidemiologist Marc Lipsitch in the journal Nature in 2015, "entails a unique risk that a laboratory accident could spark a pandemic, killing millions."

Lipsitch and 17 other scientists had formed the Cambridge Working Group in opposition. It issued a statement pointing out that lab accidents involving smallpox, anthrax and bird flu in the U.S. "have been accelerating and have been occurring on average over twice a week."

"Laboratory creation of highly transmissible, novel strains of dangerous viruses... poses substantially increased risks," the statement said. "An accidental infection in such a setting could trigger outbreaks that would be difficult or impossible to control. Historically, new strains of influenza, once they establish transmission in the human population, have infected a quarter or more of the world's population within two years." More than 200 scientists eventually endorsed the position.

The proponents of gain-of-function research were just as passionate. "We need GOF experiments," wrote Fouchier in Nature, "to demonstrate causal relationships between genes or mutations and particular biological traits of pathogens. GOF approaches are absolutely essential in infectious disease research."

The NIH eventually came down on the side of Fouchier and the other proponents. It considered gain-of-function research worth the risk it entailed because it enables scientists to prepare anti-viral medications that could be useful if and when a pandemic occurred.

By the time NIH lifted the moratorium, in 2017, it had granted dozens of exceptions. The PREDICT program, started in 2009, spent $200 million over 10 years, sending virologists all over the world to look for novel viruses and perform gain-of-function research on them. The program's funding ran out in 2018 and it wasn't renewed. Early this year, after the Trump administration drew criticism for canceling the program, it granted a six-month extension.

By the time the current pandemic hit, animal-passage experiments had become commonplace. Scientists in many of the more than 30 BSL-4 labs around the world had used them to enhance the transmissibility of respiratory-tract pathogens.

Did the work help during the current pandemic? In a recent article in the Lancet, Colin Carlson, an expert in emerging infectious diseases at Georgetown University, argued that work funded by PREDICT helped virologists rapidly isolate and classify the SARS-CoV-2 virus when it came out. However, the research "could have been better positioned for an overall impact." Although the program found hundreds of new viruses, it's nearly impossible for scientists to assess their risk to humans. The only way to tell is to "observe a human infection."

Richard Ebright, an infectious disease expert at Rutgers, put it more bluntly. "The PREDICT program has produced no resultsabsolutely no resultsthat are of use for preventing or combating outbreaks. There's no information from that project that will contribute in any way, shape or form to addressing the outbreak at hand. The research does not provide information that's useful for developing antiviral drugs. It does not provide information that's useful for developing vaccines."

China's role

The Wuhan Institute of Virology is one of many labs to receive PREDICT funding. Shi Zheng-Li, a virologist known as "bat woman" for her group's work in collecting hundreds of coronaviruses, and her staff at the Institute explored the same bat caves that were thought to have given rise to the original SARS virus in 2002. Her scientists penetrated remote caves, swabbing bats' anuses and collecting their excretions. When they returned to the lab, they cultured the viruses they found, determined their genomic sequences and tried to determine how they infect cells and animals in the lab.

The Institute began a program of gain-of-function research into bat coronaviruses in 2015. That involved taking selected strains and seeking to increase the ability of those viruses to transmit from one person to another. The gain-of-function research went hand-in-hand with the surveillance project. As scientists identified new classes of bat viruses that have the ability to infect human cells, that raised the question of what changes would have to arise in nature to make that virus transmissible in humans, which would pose a pandemic threat.

Read more

In 2015, the Wuhan lab performed a gain of function experiment using cut-and-paste genetic engineering, in which scientists take a natural virus and directly make substitutions in its RNA coding to make it more transmissible. They took a piece of the original SARS virus and inserted a snippet from a SARS-like bat coronavirus, resulting in a virus that is capable of infecting human cells. A natural virus altered with these methods would be easily flagged in a genetic analysis, like a contemporary addition to an old Victorian house.

A virus produced with animal passage methods would be much harder to spot. These viruses are not directly manipulated. When the virus passes from one animal to the next, it undergoes something similar to what would happen in the wild during the course of its evolution. A wild coronavirus passed through 10 ferrets would be difficult to identify as having been engineered or manipulated.

There is no published record of animal-passage work on coronaviruses in the Wuhan Institute. The lab got its first BSL-4 lab in 2018, which is now considered a requirement for this kind of work (though some work proceeds in BSL-3-enhanced labs). It's possible that researchers started animal passage work in the BSL-4 lab but didn't finish it in time to publish before the current pandemic, when China tightened up on publications. It's possible that the work was done in secret. It's possible that it never happened at all. But some scientists think it's unlikely that an expensive BSL-4 lab would not be doing animal-passage research, which by 2018 was not unusual.

Tracing the origins

To figure out where SARS-CoV-2 came from, Kristian Andersen of Scripps Research and his colleagues performed a genetic analysis: they published the work, which has been widely cited, on March 17 in Nature Medicine. The researchers focused on certain genetic features of the virus for telltale signs of "manipulation."

One feature was the spike of protein that the virus uses to attach so effectively to the human body's ACE2 receptors, a molecular feature of the cells in our lungs and other organs. The spike in SARS-Cov-2, the authors conclude, differs from that of the original SARS virus in ways that suggest it was "most likely the product of natural selection"in other words, natural, not manipulated in a lab.

However, the paper's reasoning as to why animal passage, in particular, can be ruled out, is not clear. "In theory, it is possible that SARS-CoV-2 acquired the... mutations during adaptation to passage in cell culture," the authors write. The theory that the virus mutated in mammalian hosts such as pangolins "provides a much stronger... explanation." Whether or not that includes animal passage in a lab, they don't say. Andersen didn't respond to Newsweek requests for comment.

Rutger's Ebright, a longtime opponent of gain of function research, says that the Andersen analysis fails to rule out animal-passage as an origin of SARS-CoV-2. "The reasoning is unsound," he wrote in an email to Newsweek. "They favor the possibility 'that the virus mutated in an animal host such as a pangolins' yet, simultaneously, they disfavor the possibility that the virus mutated in 'animal passage.' Because the two possibilities are identical, apart from location, one can't logically favor one and disfavor the other."

Read more

Jonathan Eisen, an evolutionary biologist at UC Davis, says that the preponderance of evidence, while not definitive, suggests that the virus came from nature, not a lab. "There's no hint there that there's something unnatural, that is, genetically engineered," he says. But "there is some wiggle room" in the findings that admits the possibility that the virus was concocted in a lab via animal passage. "Passaging is hard to test for. Escape from a lab is hard to test for," he says. "If [Wuhan researchers] collected something from the field and they were doing some experiments in the lab with it, and some person got infected and then it spread from there, that would be really hard to distinguish from it having spread in the field directly."

Wuhan is in possession of a virus, RATG13, that is thought to be the most similar to SARS-CoV-2 of any known virusthe two share 96 percent of their genetic material. That four-percent gap would still be a formidable gap for animal-passage research, says Ralph Baric, a virologist at the University of North Carolina who collaborated with Shi Zheng-Li on the 2015 gain-of-function research. "You keep running into problems that just don't make it likely," he says. Wuhan would probably have had to start with a virus closer to SARS-CoV-2 than RATG13, which is within the realm of possibilities.

"The only way to resolve it," says Baric, "is transparency and open science and have some real investigation into it. I don't think the Chinese are going to allow that. I don't know what any country would do in this situation. I would like to think that the U.S. would be transparent."

Jenni Fink contributed to this report

See the rest here:
The Controversial Experiments and Wuhan Lab Suspected of Starting the Coronavirus Pandemic - Newsweek

Read More...

Apic Bio Announces Presentations at the American Society of Gene and Cell Therapy’s 23rd Annual Meeting – BioSpace

Wednesday, April 29th, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Apic Bio Inc., an innovative gene therapy company developing novel treatment options for patients with rare genetic diseases, today announced that it will have three poster presentations at the American Society of Gene and Cell Therapys 23rd Annual Meeting taking place May 12-15, 2020 in virtual format. Posters will be available at http://www.asgct.org.

The posters include:

Abstract Title: High Efficiency Downstream Processing and Enrichment of Full AAV Particles Produced from Suspension HEK293 Cells (abstract #467)Presenter: Scott Loiler, Chief Technology Officer, Apic BioSession Title: Vector and Cell Engineering, Production or ManufacturingDate/Time: Tuesday May 12, 2020 5:30 PM to 6:30 PM ET

Abstract Title: Optimizing Suspension HEK293 Transfection Processes for AAV Productivity (abstract #859)Presenter: Scott Loiler Chief Technology Officer, Apic BioSession Title: Vector and Cell Engineering, Production or ManufacturingDate/Time: Wednesday May 13, 2020 5:30 PM to 6:30 PM ET

Abstract Title: Bridging Efficacy Data in an ALS Mouse Model with Clinical Route of Administration in Nonhuman Primates to Derive a Meaningful Clinical Dose Range (abstract #1114)Presenter: Randal Hand, Senior Scientist, Apic BioSession Title: Neurological DiseasesDate/Time. Thursday May 14, 2020 5:30 PM to 6:30 PM ET

About Apic Bio

Apic Bio is an innovative gene therapy company focused on developing first-in-class treatment options for rare, undertreated neurological and liver diseases. The Company's lead program is an adeno-associated (AAV)-based gene therapy for the treatment of the copper zinc superoxide dismutase 1 (SOD1) genetic form ALS. Preclinical studies of additional genetic forms of ALS (C9Orf72) and Alpha-1 Antitrypsin Deficiency (Alpha-1) are ongoing. The Company is also advancing discovery programs for two undisclosed CNS indications that leverage its proprietary silence and replace THRIVE platform. The Company is backed by leading and disease-centric investors, including Morningside Ventures, ALS Investment Fund, and The Alpha-1 Project (TAP). For more information please visit http://www.apic-bio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200428006046/en/

See more here:
Apic Bio Announces Presentations at the American Society of Gene and Cell Therapy's 23rd Annual Meeting - BioSpace

Read More...

Researchers race to find a vaccine for COVID-19 – Scot Scoop News

Wednesday, April 29th, 2020

As COVID-19 continues to rage across the U.S., scientists all over the world race to find a vaccine.

Researchers are currently testing vaccines made from genetic engineering along with the traditional vaccine, composed of the inactive virus.

A laboratory at Oxford University is preparing to begin a 6,000-person trial sometime next month, gaining a significant head start in the race to find a vaccine. Oxfords Jenner Institute performed similar inoculations for other strains of the virus last year and was able to begin scheduling tests to prove if the vaccine works.

Oxford scientists said the vaccine could have the first few million doses ready by September with regulators emergency approval, according toThe New York Times.

Another research institute, Sinovac Biotech, based in Beijing, created a trial vaccine consisting of an inactive strain of the virus and began testing on eight monkeys, and they saw no apparent side effects. They then introduced an active strain of the virus into the monkeys lungs and found that none of the monkeys developed a full infection.

However, according toScience Magazine Online, the testing group may have been too small to show results accurately, and other researchers from the University of Pittsburgh believe the way the virus stock was grown may have altered the study.

Its still too early to define the best model for studying COVID-19, a researcher at Sinovac Biotech said.

As scientists and researchers band together to find a vaccine, the effects and outcomes are still unknown, and many researchers stress that there is no promise of success with any of the current trials.

Sean Doyle, a 31-year-old medical student at Emory School of Medicine, volunteered to be one of the first people to test a vaccine. Doyle volunteered to test the vaccine on himself despite there being little known about the side effects or possible risks it could cause.

With this vaccine, no one knows what the chances are, but the potential risks are outweighed by the potential benefits of the vaccine for me. Right now, there are no great preventative measures for containing the virus, Doyle said in an interview with CNN.

Read the original post:
Researchers race to find a vaccine for COVID-19 - Scot Scoop News

Read More...

400 reads: What workers on the front line are reading – Forsyth County News Online

Wednesday, April 29th, 2020

See the full issue of the May 400 Life magazinehere.

The year 2020 has presented our county, country, and world with circumstances we were not expecting. Local residents have demonstrated a resiliency and perseverance that exemplify the true merits of our community. Many of us have been relegated to our homes, but there are those that work on the front lines, providing essential services and support. I reached out to five of my friends who continue to meet the needs of our community. Each of these accomplished women selected one book to share and we hope that these recommendations will bring you some escape and enjoyment as we continue to live our lives through this historical period. -By Becky Cahill

My book recommendation is Evvie Drake Starts Over by Linda Holmes. It is a charming novel about a recently widowed Evvie, who lives in Maine and keeps to herself after her husband passes away unexpectedly. One of her best friends, Andy, worries about her grieving and invites his childhood friend, Dean, a former major-league pitcher struggling with a case of the yips to come and live in the apartment behind Evvies house. The development of this storyline made this book an enjoyable read for me. The characters are easy to love and there is a hint of romance but its the realistic kind, with imperfect people navigating their own heartaches and perceptions of themselves. Its a warm story about friendship and finding love in unexpected ways. You only read a good book for the first time once and Evvie Drake Starts Over is a great book I never wanted to put down.

My favorite book just so happens to be a childrens book, which should come to no surprise considering my profession. Its called Love You Forever by Robert Munsch. The book is about the love a mom has for her child no matter how old they get. It begins with the mom caring for her newborn son. Every night she enters his room while he is sleeping and sings, Ill love you forever, Ill like you for always, as long as Im living, my baby youll be. She continues to sneak into his room all the way into adulthood singing the same song. One day, she is old and can no longer go into his room to sing this song. The story ends with him sneaking into his mothers room, wrapping her old frail body up into his arms, and singing, Ill love you forever, Ill like you for always, as long as Im living, my mommy youll be. I love this book because it pulls at the heart strings, and it depicts the love between a mother and child perfectly.

Behind Closed Doors by B.A. Paris is one of my all-time favorite books. In what seems to be the perfect marriage, a woman is actually held prisoner by her dashing husband. The main character, Grace, thought her life would revolve around the care of her younger sister, Millie, who has Down syndrome. She didnt expect to be swept off her feet by Jack Angel, a charming man who spoils Millie as much as he seems to love Grace. After a whirlwind courtship, Grace and Jack get married, though the wedding doesnt go smoothly, with Millie tumbling down the stairs hours before the ceremony and breaking her leg. It isnt until the couple is away on their honeymoon that the first signs of something wrong in the relationship start to show. When Millie is planning to come live with the couple, Grace schemes a way to escape Jacks clutches and save Millie from the same fate. You wont be able to put this book down to see how it ends!

Prey by Michael Crichton is a cautionary novel about advancements in nanotechnology, genetic engineering, and artificial intelligence. In Prey, an experiment has gone wrong. A cloud of nanoparticles escapes from a lab and is self-sustaining and self-reproducing. Initially programmed as imagining technology for military use, the scientists give the nanoparticles a bacterial agent to provide them the ability to work together towards a set goal. It becomes more intelligent and begins to learn from experience. The nanoparticles swiftly become a predator and become more deadly with every hour. The scientists must fight for survival and come up with a plan to eliminate the swarm. I have always been fascinated with science and technological advancements. This book catches your attention and keeps you eager to turn each page. This book is thrilling but also educational. Learning through fiction is an engaging way to pick up knowledge. The action and mystery of Prey, as well as the entertainment of the story, makes this one of my favorite books.

Published posthumously, Ill Be Gone in the Dark: One Womans Obsessive Search for the Golden State Killer details true crime author Michelle McNarmas journey to discover the identity of the Golden State Killer. The book is meticulous in the best way; Michelle provides detailed maps, victim statements, and interviews with former and current investigators. As a corporate security professional, it was fascinating to compare law enforcement investigation tactics from the beginning of the killers crime spree to present day. I was also drawn in by Michelles vulnerability, as she doesnt shy away from how the case impacted her own psyche (she notes there is a scream permanently lodged in my throat). A thoughtful, compelling work, Ill Be Gone in the Dark represents the future of true crime writing.

Becky Cahill is a career educator and an avid reader. She reads extensively in her free time and tracks her favorites (and those that arent even close)on her blog at tobereadlist.home.blog. Becky is the host of Read It or Leave It! a weekly reading podcast available on Apple Podcasts and Spotify.

More here:
400 reads: What workers on the front line are reading - Forsyth County News Online

Read More...

Intellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the American Society of Gene and…

Wednesday, April 29th, 2020

CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology bothin vivoandex vivo,announced that five abstracts were accepted for the 23rd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place virtually from May 12-15, 2020. Abstracts are available on the ASGCT website.

Intellias data include important updates about the companys progress and platform development activities:

Oral Presentations

Enhanced tgTCR T Cell Product Attributes Through Process Improvement of CRISPR/Cas9 EngineeringAs a follow-on to data presented at Keystone Symposias Engineering the Genome Conference this past February, Intellias ASGCT presentation will focus on process improvements in its CRISPR/Cas9-based engineering to deliver T cell therapies with high levels of editing, achieving robust levels of expansion, desirable memory phenotypes, improved function and reduced translocations. These platform advances support NTLA-5001, which is Intellias first wholly owned engineered T cell therapy development candidate. NTLA-5001 utilizes a T cell receptor (TCR)-directed approach to target the Wilms Tumor 1 (WT1) antigen, obtained through the ongoing research collaboration with IRCCS Ospedale San Raffaele, which is over-expressed in many hematologic and solid tumors. Intellia will focus its initial clinical investigation of NLTA-5001 on acute myeloid leukemia (AML), while exploring in ongoing preclinical studies its application in solid tumors. Intellia plans to submit an IND for NTLA-5001 for the treatment of AML in the first half of 2021.

Presenter: Aaron Prodeus, Ph.D., senior scientist, Cell TherapyAbstract number: 35Session: CAR T-Cell Therapies IPresentation date/time: Tuesday, May 12, 2020, from 11:45 a.m.-12 p.m. ET

Exploiting CRISPR-Genome Editing and WT1-Specific T Cell Receptors to Redirect T Lymphocytes Against Acute Myeloid LeukemiaThis presentation will focus on Intellias ongoing research collaboration with IRCCS Ospedale San Raffaele to apply CRISPR/Cas9 technology to develop engineered T cell therapies to address intractable cancers, such as AML. Researchers will also present data showing a significant decrease in AML tumor burden in mice treated with the WT1-specific TCRs, which are incorporated into Intellias lead NTLA-5001 candidate for the treatment of AML.

Presenter: Eliana Ruggiero, Ph.D., Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, ItalyAbstract number: 78Session: CAR T and Other Engineered T Cells Targeting Hematological MalignanciesPresentation date/time: Tuesday, May 12, 2020, from 3:45-4 p.m. ET

CRISPR/Cas9-Mediated Gene Knockout of KLKB1 to Treat Hereditary AngioedemaIntellia will present data updates on its potential hereditary angioedema (HAE) therapy, which uses the companys modular lipid nanoparticle (LNP)-based CRISPR/Cas9 delivery system to knock out the prekallikrein B1 (KLKB1) gene and reduce kallikrein activity. HAE is a rare genetic disorder characterized by recurring and unpredictable severe swelling attacks in various parts of the body, and is significantly debilitating or even fatal in certain cases. This presentation will include results from the companys ongoing collaboration with researchers at Regeneron and also will build on initial data released at Keystone Symposias Engineering the Genome Conference in February. Intellia expects to nominate a development candidate for HAE in the first half of 2020.

Presenter: Jessica Seitzer, director, GenomicsAbstract number: 1320Session: Gene Regulation and Delivery TechnologiesPresentation date/time: Friday, May 15, 2020, from 10:30-10:45 a.m. ET

Poster Presentations

Validation of CRISPR/Cas9 Off-Target Discovery Profiles from In Silico Prediction, Cell-Based and Biochemical-Based Assays with Targeted Off-Target SequencingThis presentation will highlight Intellias approach to assess off-target activity to identify highly specific CRISPR/Cas9 guides. Researchers demonstrated that potential off-target editing profiles discovered through empirical data from biochemical approaches were the most sensitive and accurate.

Presenter: Nishit Patel, Ph.D., senior associate scientist, Informatics, Computational Biology and GenomicsAbstract number: 203Session date/time: Tuesday, May 12, 2020, from 5:30-6:30 p.m. ET

In Vivo Model Development for Genome-Edited T Cell Therapeutics

Researchers will present improved murine models used to assess safety, efficacy and persistence of therapeutic modalities in cell-based therapies. Together with biotechnology company Taconic Biosciences, Intellia developed two in vivo mouse models, which allow for enhanced monitoring of graft-versus-host disease and human natural killer cytotoxicity.

Presenter: Yong Zhang, Ph.D., principal scientist, Cell TherapyAbstract number: 1174Session date/time: Thursday, May 14, 2020, from 5:30-6:30 p.m. ET

Workshop and Symposia

Building a Modular CRISPR/Cas9 Platform for Human Therapeutic ApplicationsIntellia will participate in the ASGCT Translational Science Genome Editing Pre-Meeting Workshop, which will include an overview on important factors to consider in building a modular CRISPR/Cas9 platform for human therapeutic applications.

Presenter: Jessica Seitzer, director, GenomicsSession: Gene Editing WorkshopPresentation date/time: Monday, May 11, 2020, from 4:10-4:30 p.m. ET

Industry Sponsored Symposia

Intellia will participate in an industry lunchtime panel discussion during ASGCT.

Panelist: Laura Sepp-Lorenzino, Ph.D., chief scientific officerPanel date/time: Wednesday, May 13, 2020, from 12-1:30 p.m. ET

About Intellia Therapeutics

Intellia Therapeuticsis a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or can replace patients diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more aboutIntellia Therapeuticsand CRISPR/Cas9 atintelliatx.comand follow us on Twitter @intelliatweets.

Forward-Looking Statements

This press release contains forward-looking statements of Intellia Therapeutics, Inc. (Intellia or the Company) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellias ability to advance and expand the CRISPR/Cas9 technology to develop human therapeutic products that meet the regulatory requirements in the relevant jurisdictions, as well as our CRISPR/Cas9 intellectual property portfolio; our ability to achieve stable or effective genome editing; our ability to effectively administer one dose or multiple doses of our CRISPR/Cas9 product candidates; the potential timing and advancement of our preclinical studies, including non-human primate studies for our transthyretin amyloidosis (ATTR) program (NTLA-2001) and our hereditary angioedema (HAE) program, and other studies for these and other programs, including preclinical and human clinical trials; the ability to demonstrate our platforms modularity and replicate or apply results achieved in our preclinical studies, including those in our ATTR, HAE and Wilms Tumor 1 (WT1")/acute myeloid leukemia (AML) programs or research projects, in any future studies, including human clinical trials; our ability to generate data and replicate results relating to enhancements to our proprietary lipid nanoparticle (LNP) technology, including its formulation and components, in preclinical or clinical studies, or that any enhancements will result in an improved product candidate profile; the potential development of other in vivo or ex vivo cell therapeutics of all types, and those targeting WT1 in particular, using CRISPR/Cas9 technology; our plans to submit an IND application for NTLA-2001 for ATTR in the second half of 2020, as well as for NTLA-5001, our first T cell receptor (TCR)-directed engineered cell therapy development candidate for our AML program in the first half of 2021; our plans to nominate a development candidate for our HAE program in the first half of 2020; our expectations regarding potential patient populations that may be addressed by each of our programs; actions by government agencies; our growth as a company and the anticipated contribution of the members of our board of directors and our executives to our operations and progress; the impact of our collaborations on our research and development programs; the potential timing of regulatory filings regarding our development programs; the potential commercial opportunities, including value and market, for our product candidates; our expectations regarding our use of capital and other financial results during 2020; and our ability to fund operations through the end of 2021.

Any forward-looking statements in this press release are based on managements current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellias ability to protect and maintain its intellectual property position; risks related to Intellias relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to the initiation and conduct of studies and other development requirements for its product candidates; the risk that any one or more of Intellias product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; and the risk that Intellias collaborations with Regeneron, OSR or its other collaborations will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellias actual results to differ from those contained in the forward-looking statements, see the section entitled Risk Factors in Intellias most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties, and other important factors in Intellias other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.

Intellia Contacts:

Media:

Lynnea Olivarez

Director

External Affairs & Communications

+1 956-330-1917

lynnea.olivarez@intelliatx.com

Investors:

Lina Li

Associate Director

Investor Relations

+1 857-706-1612

lina.li@intelliatx.com

Read the original here:
Intellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the American Society of Gene and...

Read More...

Could Cannabis Be an Effective Treatment for COVID-19? – Lab Manager Magazine

Wednesday, April 29th, 2020

With COVID-19 continuing to spread all over the world, researchers are looking into numerous options for possible treatment, including existing drugs. Medical cannabis is one option thats gained a lot of attention, but while early research shows some promise, its much too early to be considered a safe and effective treatment.

Likely due to the continued restrictions on cannabis research in the US, there are not yet any studies in the country focusing on cannabis as a possible treatment or prevention for COVID-19. However, earlier this month, University of Miami researchers launched a study into how the novel coronavirus is impacting American cannabis users during the peak of the outbreak.

The global qualifying conditions for medical cannabis, though not uniform, all include individuals with compromised immune systems and other chronic health conditions. Therefore, this is a population that we cannot forget about in our joint effort to flatten the curve,'" Denise C. Vidot, an assistant professor in the School of Nursing and Health Studies and a trained epidemiologist, said in a press release.

More recently, a partnership between cannabis research companies Pathway RX and Swysh Inc. and the University of Lethbridge in Alberta, Canada, found that certain Cannabis sativa extracts could be used in treatments to prevent infection with SARS-CoV-2, the virus that causes COVID-19.

Specifically, they found that the extracts have an effect on the expression of ACE2 and TMPRSS2, proteins in human cells that research has shown to be an entry point for the virus. However, their research has only just been submitted for publication and has not yet been peer reviewed.

While our most effective extracts require further large-scale validation, our study is crucial for the future analysis of the effects of medical cannabis on COVID-19, the researchers said in an early pre-publication version of their study. The extracts of our most successful and novel high CBD [cannabidiol] C. sativa lines, pending further investigation, may become a useful and safe addition to the treatment of COVID-19 as an adjunct therapy.

They add that their extracts could potentially be used in a mouthwash or throat gargle to prevent COVID-19 coronavirus infection.

Similar research was recently launched in Israel. InnoCan Pharma Ltd, an Israeli pharmaceutical company focused on cannabis therapies, announced Apr. 17 that it is partnering with Tel Aviv University to develop a possible cell therapy treatment that uses CBD-loaded exosomes to treat those with COVID-19. The product, which the company says will likely be given to patients through inhalation, will also be tested as a treatment for other lung infections.

Exosomes are small particles created when stem cells are multiplied, InnoCan said in a recent statement. Exosomes can act as homing missiles, targeting specific damaged organs and have an important role in cell-to-cell communication. When the cell healing properties of the exosomes are combined with the anti-inflammatory properties of CBD, it is expected to reach high synergetic effect.

Also in Israel, the Medical Cannabis Network reports that researchers at the Israel Institute of Technology and their partners are working on two studies exploring the use of a cannabis terpene formulation, also administered by inhalation, in the treatment of COVID-19. The first study will focus on the effect of Cannabis molecules on the immune system, while the second study will investigate the ACE2 receptor and how the terpene treatment could prevent viral entry to human cells through this pathway.

Another Israeli cannabis research company, Stero Biotechs, was also to launch a small clinical trial this month studying the effectiveness of a CBD-steroid treatment in 10 COVID-19 patients at Rabin Medical Center, according to an Apr. 19 press release.

This isnt the first time cannabis has been investigated as a prevention and treatment strategy for a coronavirus. Earlier research has looked at the drugs effect on SARS-CoV, the coronavirus that causes Severe Acute Respiratory Syndrome, which caused an outbreak in 2003. In a 2007 study, researchers from China examined the antiviral properties of cannabis against SARS-CoV.

They looked at 221 phytocompounds, finding that specific abietane-type diterpenoids and lignoids exhibit strong anti-SARS-CoV effects.

However, those thinking of upping their cannabis intake in the hopes of preventing or treating COVID-19 infection should take these early results with a large grain of salt. In particular, smoking more cannabis is likely to put people at greater risk of infection, health authorities stress.

The research community should be alert to the possibility that [COVID-19] could hit some populations with substance use disorders particularly hard, the US National Institute on Drug Abuse says in a statement. Because it attacks the lungs, the coronavirus that causes COVID-19 could be an especially serious threat to those who smoke tobacco or marijuana or who vape.

As for those wondering if edibles or oils are a safer solution, there just isnt enough research to prove these products are truly effective against COVID-19 either.

With current research on cannabis as a COVID-19 prevention and treatment strategy still in the very early stages, it will likely be some time before we have a clear answer as to whether these products are safe and effective options. The studies in Israel have only just been launched with no solid timeline on when the results will be out, and the Canadian researchers are still looking for partners to run clinical trials with their cannabis extracts.

While it will likely be frustrating for those who want a clear answer now, it will be many months before we know for sure whether cannabis is a safe and effective option against COVID-19.

Editors note: So far, there is no approved treatment or vaccine for COVID-19. This article is meant to be a summary of some of the research so far into cannabis as a possible COVID-19 treatment, not an endorsement of its use as such. With the COVID-19 situation rapidly changing, always consult your local health authority and health care provider for the most up-to-date information on treatment options and cannabis use during the pandemic.

Read more here:
Could Cannabis Be an Effective Treatment for COVID-19? - Lab Manager Magazine

Read More...

The Republicans who were once so pro-life they fought over one woman on life support now want to sacrifice grandma for the economy – The Independent

Wednesday, April 29th, 2020

Years after the United States elected a president with the motto America First, we just pulled ahead in a race no one wants to win: the most deaths from the novel coronavirus. In order to limit casualties from a catastrophic second wave, states have enacted measures of differing severity, from shutting down some businesses to move severe shelter in place orders mandating citizens stay in their homes.

However, months into this disruption, some restless Americans are looking for a way out and there are Republican politicians eager to placate them. Senator Rand Paul of Kentucky bemoaned the lack of commerce on Twitter and threw his support behind re-opening the economy. Georgia Governor Brian Kemp is way ahead of him, announcing plans to lift restrictions on businesses from bowling alleys to hair salons amidst widespread pushback in his own state. Lt. Governor Dan Patrick of Texas skipped the subtext and went straight to the point with the breathtaking assertion that there are more important things than living, a statement that presumably doesnt include himself or his loved ones.

Its puzzling how these politicians think re-opening will lead to business as usual with an unpredictable contagion floating around. Commerce relies on consumers, and if a majority of those consumers are rightfully afraid for themselves and their families, how exactly is the government supposed to put things back to pre-pandemic levels without forcing us to go to the mall on pain of arrest?

Sharing the full story, not just the headlines

Even if they just intend to let those who dont care about the risks shop, go to work and pretend everything is normal, theres a very real danger that way more Americans will die as a result. But according to Lt. Gov. Patrick, its a justifiable sacrifice for the good of the nations GDP.

This is fascinating coming from a party that has long labeled itself as pro-life over the years when it suits them. Lets look at one of the most extreme examples: Terri Schiavo, a woman whose private medical battle became a tool for the Republican party during the early 2000s. After a Florida trial court concluded that Schiavo was in a persistent vegetative state and would have wanted the feeding tube keeping her alive to be removed, Republicans at all levels became involved. Governor Jeb Bush pulled in everyone from his brother in the White House to the United States Congress to unsuccessfully fight the trial courts order for years. It would seem to a casual observer that this was a political party that would stop at nothing to save a life.

This wasnt the first time Republicans (or the Bushes) were performatively pro-life. During his first year in office President George W. Bush severely limited federal funding for research involving embryonic stem cells, giving evangelical conservatives an important win. Bush continued to oppose bills to loosen these restrictions, citing concerns that taxpayers would be funding the destruction of potential life. Again, if you didnt know anything else about the GOP you would think that their concerns were so pure as to encompass cells that could become a human being someday.

This stated concern for life didnt stop with the Bush brothers. Republicans took a stand during debates surrounding President Obamas signature legislation, the Affordable Care Act. This proposed legislation aimed to increase the amount of people with health insurance (which is positively correlated with life preservation). However, former GOP vice presidential candidate Sarah Palin asserted repeatedly that the law would lead to death panels that would decide whether elderly Americans would live or die. Inspired by Palin, the right painted a dystopian picture of a future where liberal judges would decide grandmas fate. A decade later and pearl-clutching at treatment of older Americans has taken a turn since they are inconveniently deemed to be more at risk of dying of Covid-19. Now the elderly, it seems, are at best inessential to public life and, at worst, expendable sacrifices to the gods of capitalism.

Here is whats revealing in each of those episodes: championing the life of Terri Schiavo, or the potential life of stem cells, or the imaginary life of a condemned grandma didnt cost Republicans a nickel. But the people who would potentially die if re-opening measures are scaled back are expensive. Theyre also inconvenient for the partys narratives. They include the medical workers who counter-protest the Confederate flag-wavers who want to be able to get a haircut. They are immigrants who risk their lives to provide you with food. They are, disproportionately, black, indicative of the virulent racism in our country.

Championing their lives means economic sacrifice with no legislative gain. That is, apparently, a bridge too far.

Link:
The Republicans who were once so pro-life they fought over one woman on life support now want to sacrifice grandma for the economy - The Independent

Read More...

Russia’s Humanitarian Law Obligations to Civilians in Occupied Ukrainian Territories in the Time of COVID-19 – Just Security

Wednesday, April 29th, 2020

(Editors note: This is the first of a two-part analysis by Global Rights Compliance of the application of international humanitarian law (IHL) in areas under occupation during the coronavirus pandemic, with the Russian occupation of parts of Ukraine as a case in point. Part 1 discusses Russias obligations and compliance in protection of civilians from the effects of the virus. Part 2 will consider to what extent Ukraine, as the displaced sovereign, retains residual obligations to provide further protection.)

As the coronavirus works its way across the globe, compliance with international humanitarian law (IHL) standards is paramount for the protection of survivors of armed conflict. The pandemic particularly highlights the vulnerability and conversely, the legal rights of populations living under occupation, whose lives depend on the willingness of the occupying State to abide by the letter and spirit of IHL.

The Russian Federations occupation of parts of Ukraine is a useful example. Ukraine is one of 10 States and territories currently under foreign occupation in the world. The others are: Azerbaijan, Cyprus, Eritrea, Georgia, Lebanon, Moldova, Palestine, Syria and Western Sahara. (see here, p. 32). Occupying powers in these territories are bound by a range of specific obligations under IHL related to providing health care for the populations living under their control. Non-compliance with these obligations can have harmful, if not catastrophic, consequences for these populations, especially in the midst of a crisis as deadly as the coronavirus pandemic. This is especially so in the frequent scenario wherein the occupier disputes its status as an occupying power and therefore, refuses to assume its IHL obligations.

The following discussion is premised on the clearest of legal indications that the Russian Federation is an occupying power in Crimea and bound by a panoply of IHL obligations that require a robust response to any public health crisis to ensure that the civilian populations medical and health requirements are met. There is international consensus on the occupied status of Crimea (see here, here and here). The Russian Federation has been an occupying power in Crimea and, arguably, eastern Ukraine since 2014 (for more information, see here and here). Whilst the Kremlin disputes this status, they are alone in this view.

The situation in eastern Ukraine and the question of Russias IHL status is more complicated. Since 2014, two non-State armed groups (NSAGs) the Donetsk Peoples Republic (DPR) and the Luhansk Peoples Republic (LPR) have exercised territorial control over parts of eastern Ukraine. For the purposes of this analysis, the question may be viewed as one of control, namely who is in actual control: the Russian Federation or these NSAGs (which themselves, are unquestionably supported by Russia) that purport to independently administer the territory?

If the Russian Federation exercises overall control over these NSAGs, it follows that it is to be legally deemed an occupying power (see, Blaki Trial Judgment, para. 149) and is therefore obligated to fulfil all IHL obligations applicable to an international armed conflict (IAC) (as outlined below). In the event that the facts do not meet this threshold, the DPR and LPR, as NSAGs exercising control over parts of eastern Ukraine, will themselves be required to meet a range of less demanding and detailed (but, nonetheless, still considerable) IHL obligations applicable to non-international armed conflicts (NIACs).

The Overall Control Test

Legally speaking, the overall control test dictates when a State is deemed responsible for the actions of a NSAG, or other non-state actor. Overall control exists where the State in question has a role in organising, coordinating or planning the military actions of the military group, in addition to financing, training and equipping or providing operational support (see the Tadi Appeal Judgment, para. 137, and GRCs note on the subject). In the words of the late international law luminary Antonio Cassese, the State in question must have a say in and an impact on, the planning and organisation of the groups activities (see here, p. 661). The extent of this impact must go beyond mere coordination and cooperation between allies (see Tadi, para. 152). Whether overall control exists is a factual determination, made on a case-by-case basis.

Differing from the International Court of Justices effective control test, the overall control test does not require a demonstration that the State in question planned or directed all of the relevant groups actions, issued specific orders and instructions on the conduct of military operations or chose the groups targets (Tadi, para. 137). Instead, the existence of overall control may be inferred in the following circumstances: (i) the State generally directs, coordinates or helps the armed group in its actions, including by participating in the planning and supervision of its military operations, (ii) the State exercises control over the political and military objectives of the group, and (iii) the group is (financially or otherwise) dependent on the State (Tadi, paras. 138, 145, 150-154; and Cyprus v. Turkey, in the European Court of Human Rights, para. 77).

Regrettably, in-depth analysis of this threshold has been lacking both in and out of Ukraine. Nevertheless, there are strong indications that the Russian Federation is in overall control of the DPR and LPR. First, despite repeated denials by Russian officials, there is mounting evidence of direct Russian military involvement in the conflict in support of the DPR/LPR. To this day, despite purporting to play a neutral role in the ceasefire and peace talks in eastern Ukraine, it appears that the Russian Federation has not only trained, armed and equipped the DPR/LPR forces, but also coordinated with them in the planning and execution of military operations against the Ukrainian armed forces (see here and here). This includes the direct participation of Russian troops in hostilities in support of DPR/LPR forces (including by cross-border shelling from Russian territory), as well as the provision of military training and the transfer of large quantities of advanced weaponry, including defense systems, artillery, tanks and armored personnel carriers, to these groups (see the International Criminal Court Prosecutors 2017 Preliminary Examination Report on the situation in Ukraine at para. 92; see also here, here, here, here, here, here and here). By March 2, 2015, the U.S. Army Europe Command estimated that 12,000 Russian soldiers including military advisers, weapons operators and combat troops were active in eastern Ukraine.

Still, the question remains whether this far-reaching assistance indicates a relationship of cooperation/coordination between allies or of overall control. Recent developments in litigation concerning the downing of flight MH17 in Dutch courts provide further insights into the likely role of the Russian state. Three of the individuals indicted in the case, due to the leading role they played in the commission of the crime (Igor Girkin, Sergey Dubinsky and Oleg Pulatov), are Russian nationals and former members of the GRU and FSB, the two main Russian intelligence agencies. At the time of the incident, these individuals also held high-level positions in the DPR (Girkin was the Minister of Defense; Dubinsky was Girkins deputy and the head of the DPRs intelligence service; and Pulatov was Dubinskys deputy). These facts suggest that the role played by the Russian Federation in the DPRs military operations goes far beyond mere coordination or provision of training and arms. Rather, it seems that, through its operatives, the Russian Federation has directly participated in the organization, planning and supervision of the DPRs military operations.

This is an illustrative demonstration of the Russian Federations modus operandi in exercising control over eastern Ukraine: infiltrating the higher echelons of DPR/LPR governmental structures with Russian operatives (and eliminating any dissenting elements therein), allowing Russia to exert control over the military objectives and actions of these groups, while at all times retaining a measure of plausible deniability (see here, here and here). Such control, however, is not limited to the military sphere. An email leak in October 2016 revealed how the Russian Federation also manages and controls political developments within the DPR and LPR, for instance, by vetting/reviewing prospective members of their respective governments (for a detailed analysis, see here).

Moreover, and of particular note during the time of COVID-19, is the degree of financial dependency. The Russian Federation supports the economies of these entities by spending an estimated $2 billion annually in non-military expenditures in eastern Ukraine. In 2015, the Russian Federation began paying pensions, benefits, and wages to members of both entities, leading to significant economic dependency.

In sum, the level of Russian involvement in military, political and financial spheres have led commentators to conclude that the LPR and DPR are not autonomous actors but in fact, puppets that operate under the complete and direct military and political control of the Russian Federation (see here, here and here). While this analysis is based in part on the geopolitical realm, there does appear to exist substantial legal reason to believe that Russia is in overall control of both the LPR and DPR and thus, legally qualifies as an occupying power in eastern Ukraine.

Russias IHL Obligations

IHL provides occupying powers with an overarching duty to restore and ensure public order and safety within occupied territories (Hague Regulations, Art. 43). This obligation derives from their forceful supplanting of the authority and control of the prior sovereign power and consequent disruptions to the provision of essential public services to the population. IHL requires the occupying power to assume responsibility for these services.

Provision of health care is one such service. The occupying power has the duty to ensure public health and hygiene in occupied territories and meet the medical needs of the population without any adverse distinction (See Geneva Convention IV, Arts. 27, 55 and 56; and Additional Protocol I, Art. 14). According to the International Committee of the Red Cross (ICRCs) influential commentaries to the Geneva Conventions, Article 55 of the Fourth Geneva Convention requires an occupying power to maintain at a reasonable level the material conditions under which the population of the occupied territory lives. To this end, and to the fullest extent of the means available to it, the fourth Geneva Convention stipulates in Article 56 that an occupying power must maintain hospital establishments and related services, including by promptly organizing new hospitals if necessary. Medical services must be of good quality, meaning that they are provided in facilities that satisfy certain minimum standards (such as having access to safe and potable water and adequate sanitation) and staffed by skilled medical personnel who treat patients using appropriate medications and equipment (see this influential commentary on the Geneva Conventions, p. 1498). Similar, but less detailed, obligations apply to NSAGs during NIACs (see Geneva Conventions I-IV, especially Common Article 3; Additional Protocol II, Art. 7; Rule 110 of the ICRCs study of customary IHL; and the ICRCs Commentary on the Additional Protocols, p. 1409).

Additionally, the occupying power must ensure that adequate medical supplies are available to meet the needs of the population of the occupied territory, including by procuring such supplies when necessary (Geneva Convention IV, Art. 55). If the population is inadequately supplied, the occupying power must agree on relief schemes with other States or impartial humanitarian organizations (such as the ICRC) to allow and facilitate the provision of medical aid to the population (Geneva Convention IV, Arts. 23, 59). For rules applicable to NIACs, see Additional Protocol II, Arts. 9 and 18; ICRC Rule 55).

Particularly relevant to the current crisis, an occupying power is required to adopt and apply prophylactic and preventive measures necessary to combat the spread of contagious diseases and epidemics (Geneva Convention IV, Art. 56). As noted in the authoritative ICRC commentary, measures taken to satisfy Article 56 should include:

supervision of public health, education of the general public, the distribution of medicines, the organisation of medical examinations and disinfection, the establishment of stock of necessary medical supplies, the despatch of medical teams to areas where epidemics are raging, the isolation and accommodation in hospital of people suffering from communicable diseases, and the opening of new hospitals and medical centres.

These obligations are broadly consistent with the World Health Organization (WHO) guidelines on ensuring public health and safety during the COVID-19 pandemic. In short, WHO advises States to, among other things: (i) communicate to the public the facts about the pandemic, (ii) adopt public health measures, such as social distancing and travel-related measures, (iii) identify, isolate and provide optimized care for infected patients, especially those who are particularly vulnerable, and (iv) enhance the preparedness and capacity of health care facilities (including the knowledge of the medical personnel) to meet expected surges in COVID-19 cases (see also here and here).

Russias Response to COVID-19 in Crimea and Eastern Ukraine

An examination of the Russian Federations response to the COVID-19 pandemic in Crimea and eastern Ukraine exposes a range of deficits that likely entail breaches of various IHL obligations.

As of April 21, there were 46 confirmed cases of COVID-19 in Crimea and 57 in relevant parts of eastern Ukraine (36 in DPR controlled areas and 21 in LPR controlled areas). There is, however, reason to doubt the accuracy of these figures. Firstly, in a general sense, neither the Kremlin nor its agents are known for their truthfulness and transparency in normal times, let alone during times of urgency or emergency. Ukrainian authorities claim that the DPR and LPR authorities have suppressed actual infection and mortality figures (see here and here). Doctors are purportedly being silenced, including being required to sign non-disclosure forms and to re-classify autopsy reports. Similar claims have been made by Ukrainian Ombudsman Lyudmila Denisova in relation to the spread of coronavirus in Crimea. These claims, if true, point to a deliberate attempt on the part of Russian occupation authorities to avoid their responsibilities to the populations of Crimea and eastern Ukraine by keeping them (and the international community) in the dark.

Further evidence of this neglect may be seen in the introduction of emergency measures in Crimea. Despite the preventative measures the Russian Federation took within Russia itself to curb the spread of the coronavirus as early as January, corresponding measures apparently were not put in place in Crimea until March 17. Enacted measures include prohibitions on sports, cultural, public, and other large gatherings; suspension of the activities of restaurants, cafes, education institutions, and public transportation services; isolation of individuals arriving in Crimea from other territories of the Russian Federation; and mandatory quarantine measures and travel restrictions (see here, here and here). Similar, albeit milder, measures have been put in place by the DPR and LPR authorities (see here).

The adoption of these physical distancing measures is certainly a step in the right direction. Nevertheless, as will be discussed below, the Russian occupation authorities appear grossly ill-prepared to take the further steps necessary to comply with their IHL obligations.

The Inadequacies of Health Services in Crimea and Eastern Ukraine

The Russian health-care system introduced into Crimea after the occupation is beset with major shortcomings across a range of essential services relevant to the treatment of infectious diseases. Of significant relevance to IHL obligations more broadly, and in direct contravention of the specific requirement that the provision of health care in occupied territory be made without any adverse distinction (see Geneva Convention IV, Art. 27), is that Ukrainian citizens who refuse to acquire Russian citizenship and residence permits are denied access to medical services (see here, pp. 11-12).

Similarly, Russian authorities seem to be failing to maintain the health services at a reasonable standard to meet the medical needs of the population in Crimea and eastern Ukraine. Local residents report that the conditions in Crimean medical facilities do not satisfy basic sanitary standards. For example, the mother of a teenage patient exposed the inadequate conditions in the Kerch City Hospital in the east of Crimea, which lacks access to running water, sufficient heating, and electricity. Another resident shared photos from the main Bakhchisaray and Yalta City Hospitals, revealing the unsanitary conditions there, including fungus growth on the walls and soiled bedsheets. In Sevastopol City Hospital, on the other hand, patients complain that there is only one functioning toilet for 60 people.

Moreover, according to the Crimean Human Rights Group, the number of medical personnel who know how to treat COVID-19 patients in Crimean hospitals is extremely low, meaning that proper COVID-19 testing, diagnosis, and treatment remains the exception. Rather than conducting appropriate medical examinations and isolating/treating COVID-19 patients at hospitals, medical personnel send those who show symptoms home to self-isolate. Even the relatives or other persons living in the same household with those who were diagnosed with COVID-19 are denied testing and admission to hospitals.

These shortcomings have already proven to be deadly for those most vulnerable. On March 31, a 65-year-old resident of Kerch with a high fever and heavy coughing was denied admission to a hospital by the emergency medical staff. He was admitted to the intensive care unit two days later with more severe symptoms, where he eventually died. His family was not informed of the cause of his death.

While there is not the same amount of information available in Donetsk and Luhansk, even more serious problems appear to undermine medical responses there. As outlined by the United Nations, people (especially older persons) residing in eastern Ukraine conflict zones, including numerous isolated villages, face serious limitations in accessing vital healthcare due to the distance, the cost of travel, the unavailability of medication, medical personnel, and lack of transportation such as ambulances (see here, here, para. 36 and here para. 7).

Lack of Adequate Medical Supplies

Lastly, both Crimea and eastern Ukraine seem to be under-resourced in relation to the type of medical supplies necessary to help stem the spread of, or treat those infected with, the coronavirus. Activists across six Crimean cities checked 16 pharmacies and reported there to be no face masks or hand sanitizers available, and shortages on medications. The main hospitals in Armyanks and Sevastopol City, on the other hand, lack sufficient protective equipment for both health workers and patients.

Further, throughout Crimea (with a population of more than 2 million), the medical facilities where COVID-19 patients are treated have a total of 212 ventilators available. Similarly, even these limited resources are largely unavailable in Donetsk and Luhansk. According to LPR medical professionals, local hospitals are unprepared to deal with a near-inevitable COVID-19 outbreak and lack the resources to treat any high number of patients. A report by Ukrainian authorities noted that Donetsk and Luhansk residents showing symptoms of COVID-19 are often diagnosed with general viral infections and sent home, in large part due to the lack of medical personnel, test kits, and hospital beds.

These shortcomings indicate that the Russian Federation is failing to respond to the COVID-19 pandemic in any meaningful way in line with its obligations under IHL. Russian authorities do not have to do the impossible nor achieve perfection. Rather, the Russian government must urgently utilise all the means at its disposal (i.e. the fullest extent of means available to it) to bring the health-care standards in Crimea and eastern Ukraine to a reasonable level. That includes: (i) improving the conditions and resources of the existing medical facilities, (ii) establishing new medical facilities if needed, and (iii) ensuring that the medical supplies necessary to address COVID-19 are adequate for the population (see ICRC Commentary on Geneva Convention IV, Arts. 55 and 56).

Any claim by Russia to not having the means to improve health conditions in occupied areas of Ukraine should be carefully scrutinized. Of particular concern is Russias apparent lack of effort to fulfil the WHOs recommendations that require, at a minimum, enhancement of the capacity of health facilities (including expert medical personnel) to address the elevated and specific demands corresponding to the coronavirus pandemic. Moreover, any bona fide claim along these lines would need to be evidenced by Russian efforts to reach agreements with other States or impartial organizations such as the ICRC to allow and facilitate required medical assistance to the occupied territories (see ICRC Commentary on Geneva Convention IV, Art. 59). In sum, as the 11th largest economy in the world, the Russian Federation has an uphill battle to convince the international community that it does not have the material resources to meet these obligations.

Russias IHL Obligations to Confined Persons

IHL provides specific health safeguards for persons who are deprived of their liberty in occupied territories because they are particularly vulnerable. Detained or interned persons must be: (i) kept in conditions of hygiene sufficient to ensure good health, (ii) provided with any medical attention they require, and (iii) given the right to be visited by ICRC personnel (see Geneva Convention IV, Arts. 76, 81; for NIACs see Additional Protocol II, Art 5(1)(a), (2)(d) and ICRC Rules 118).

WHO guidelines on responding to the pandemic in prisons and other places of confinement provide some insights on what these obligations may entail. According to WHO, incarcerated persons should: (i) be protected from infection by screening those who access the prison and adopting social distancing measures, (ii) be given adequate space, air exchange, and routine disinfection of their environment, (iii) receive access to adequate health care, personal hygiene facilities (e.g. hot water and soap), and protective equipment such as masks and gloves, without discrimination, (iv) be screened for COVID-19 symptoms and put in medical isolation for further medical evaluation/testing if need be, (v) be treated on-site or be transferred to specialist facilities if they have contracted COVID-19, and (vi) be allowed to receive visits from international or domestic monitoring organizations.

Detention Conditions in Crimea and Eastern Ukraine

Conditions imposed on detainees in occupied Crimea and eastern Ukraine fall significantly short of IHL requirements and WHO standards and regretfully, pave the way for a perfect storm in the event of a coronavirus outbreak in the region. Reportedly, detention facilities in Crimea lack medical staff, medications, equipment (such as masks or ventilators) as well as expertise in the treatment of COVID-19 patients. Sanitation and hygiene conditions are extremely poor. Detainees do not have adequate access to water or ventilation and live in overcrowded cells. Prisoners risk infection due to daily inspections and searches conducted by the prison staff who carry out their duties without any protective equipment. No social distancing measures are in place.

More disturbingly, those who show symptoms of COVID-19 are denied appropriate medical treatment, testing, or hospitalization, significantly increasing the likelihood of infecting other prisoners as well as staff. For instance, Server Mustafayev, a Crimean Tatar prisoner of conscience and the coordinator of the civil society organization Crimean Solidarity was denied any meaningful medical attention or hospitalization, even though he was suffering from a dry cough and breathing difficulties with a fever and temperature of 39.3 C (102.7 F). Instead, he was forced to appear in a court hearing and is still being kept in a pre-trial detention cell with other detainees.

The situation in eastern Ukraine is even worse. Conditions in the detention centers in the DPR and LPR would test the strength of a healthy person in the best of times. The latest report on Ukraine by the U.N. Office of the High Commissioner for Human Rights (OHCHR) tells its own shocking story of intentional cruelty and neglect torture and ill-treatment including beatings, stress positions, electric shocks, asphyxiation, sexual violence, deprivation of water, food, sleep, or access to a toilet (para. 69).

Only recently, more than 100 civil society organizations worldwide appealed for international intervention to help prevent the spread of COVID-19 in the prisons of Ukraines occupied territories. Aside from these horrendous acts outlined by the U.N. human rights commissioner, cells lack light and are overcrowded, lack proper heating and sanitation, and are overflowing with sewage and vermin (including insects and rats). Ordinarily, detainees rely on their relatives for food and medication, but due to COVID-19 movement restrictions, family members are no longer able to access detention centers (see here and here).

In light of this systematic ill-treatment and the fact that ICRC and U.N. officials are still not provided access to detained persons held in official (let alone unacknowledged) detention centers, there is nothing to suggest that there will be any change in the near future, let alone anything resembling adequate medical protection from the spread of this pernicious infection.

Conclusion

There is little to suggest that Russia will accept or respect binding IHL obligations clearly mandating firm and decisive action to protect the health of populations in occupied Ukrainian territories. Indeed, the last five years of occupation have led to a range of IHL violations, some of which may amount to war crimes.

This rather gloomy assessment is not intended to inspire despair, but rather to reinforce the pressure that will be needed to achieve constructive change before it is too late. Common Article 1 of the Geneva Conventions, as interpreted by the International Court of Justice (see para. 158), requires every State Party, whether or not it is a party to a specific conflict, to ensure that the provisions of these instruments are complied with. As discussed above, Russia is obliged to provide adequate health care and medical supplies to the populations of Crimea and eastern Ukraine to counter the COVID-19 pandemic or, if unable to do so, reach agreements with other States or impartial organizations such as the ICRC to allow and facilitate the provision of appropriate medical assistance to these territories.

Compliance has its advantages for the Russian Federation as well. By strengthening its COVID-19 response and meeting its obligations under international law, Russia can avoid a full-blown epidemic within the territories it occupies. Not only would this be useful in the protection of its own territory from the coronavirus, it would also boost its credibility as part of the international community.

Time may be running out and, as we have seen throughout the world, action taken early and decisively remains the best protection against the spread of the virus and to ultimately save lives.

Read more here:
Russia's Humanitarian Law Obligations to Civilians in Occupied Ukrainian Territories in the Time of COVID-19 - Just Security

Read More...

Neuropathy Pain Treatment Market Giants Spending Is Going To Boom – Cole of Duty

Tuesday, April 28th, 2020

Research report on global Neuropathy Pain Treatment Market 2020 with industry-primary research, secondary research, product research, size, trends, and Forecast.

The Neuropathy Pain Treatment report provides independent information about the Neuropathy Pain Treatment industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies profiles including business overview and recent development.

Download Premium Sample Copy Of This Report: Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Neuropathy Pain Treatment Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of Neuropathy Pain Treatment Market: Products in the Neuropathy Pain Treatment classification furnish clients with assets to get ready for tests, tests, and evaluations.

Major Company Profiles Covered in This Report

Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals

Table Of Content

Market Overview: Scope & Product Overview, Classification of Neuropathy Pain Treatment by Product Category (Market Size (Sales), Market Share Comparison by Type (Product Category)), Neuropathy Pain Treatment Market by Application/End Users (Sales (Volume) and Market Share Comparison by Application), Market by Region (Market Size (Value) Comparison by Region, Status and Prospect

Neuropathy Pain Treatment Market by Manufacturing Cost Analysis: Key Raw Materials Analysis, Price Trend of Key Raw Materials, Key Suppliers of Raw Materials, Market Concentration Rate of Raw Materials, Proportion of Manufacturing Cost Structure (Raw Materials, Labor Cost), Manufacturing Process Analysis

Neuropathy Pain Treatment Market Report Covers the Following Segments:

Segment by Type:

Calcium channel alpha 2-delta ligandsSerotonin-norepinephrine reuptake inhibitorsOthers

Segment by Application:

Retail PharmaciesHospitalsOthers

North America

Europe

Asia-Pacific

South America

Center East and Africa

United States, Canada and Mexico

Germany, France, UK, Russia and Italy

China, Japan, Korea, India and Southeast Asia

Brazil, Argentina, Colombia

Saudi Arabia, UAE, Egypt, Nigeria and South Africa

Key Benefits for Stakeholders

The study provides an in-depth analysis of the Neuropathy Pain Treatment market size along with the current trends and future estimations to elucidate the imminent investment pockets.

Information about key drivers, restraints, and opportunities and their impact analysis on the market size is provided.

Porters five forces analysis illustrates the potency of buyers and suppliers operating in the portable gaming industry.

The quantitative analysis of the Neuropathy Pain Treatment industry from 2020 to 2026 is provided to determine the Neuropathy Pain Treatment market potential.

About (Market Research Bazaar):

Market Research Bazaar (MRB)- a part of VRRB Reports LLP is an overall Market Research and consulting organization. We give unparalleled nature of offering to our clients present all around the world crosswise over industry verticals. Market Research Bazaar has aptitude in giving profound jump showcase understanding alongside advertise knowledge to our clients spread across over different endeavours.

Media Contact:

Market Research Bazaar

UK: +442070973908

US: +13156360953

India: +919548234540

Email:[emailprotected]

Website:http://marketresearchbazaar.com/

Blog:http://marketresearchbazaar.com/blogs

See the article here:
Neuropathy Pain Treatment Market Giants Spending Is Going To Boom - Cole of Duty

Read More...

Diabetic Neuropathy Market Global Status and Business Outlook 2018 to 2026 – Latest Herald

Tuesday, April 28th, 2020

Diabetic Neuropathy Market Research Report 2020, is mostly driven by the improved taking on of Diabetic Neuropathy across small and medium-sized enterprises. Worldwide Diabetic Neuropathy Market quantifying the talk on those players at the interval. The report figures the limits and strong points of the players. To begin with the Diabetic Neuropathy Market report which covers market characteristics, industry structure and comitative landscape, the problems, desire concepts, along with business strategies market effectiveness.

Ask For Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/213

About Diabetic Neuropathy Market Report

This research report categorizes the global Diabetic Neuropathy Market by players/brands, region, type and application. This report also studies the global market status, competition landscape, Market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porters Five Forces Analysis.

Market Competition by Top Key Players/Manufacturers:

Eli Lilly and Company, GlaxoSmithKline, Pfizer, Johnson & Johnson and Janssen Pharmaceuticals.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/213

Diabetic Neuropathy Market Dynamics in the world mainly, the worldwide 2020-2026 Diabetic Neuropathy Market is analyzed across major global regions. CMI also provides customized specific regional and country-level reports for the following areas:

Major Highlights of the Diabetic Neuropathy Market Report:

Diabetic Neuropathy Market Overview, Market shares and strategies of key players, Sales Market Forecast, Manufacturing Analysis of Diabetic Neuropathy, Market Driving Factor Analysis of Diabetic Neuropathy, Market Competition Status by Major Manufacturers, Upstream and Downstream Market Analysis of Diabetic Neuropathy, and Cost and Gross Margin Analysis of Diabetic Neuropathy.

Why This Report is Useful? It helps:

1. The report will include the qualitative and quantitative analysis with Diabetic Neuropathy Market estimation and compound annual growth rate (CAGR) between 2020 and 20262. Assess the Diabetic Neuropathy production processes, major issues, and solutions to mitigate the development risk.3. Comprehensive analysis of market dynamics including factors and opportunities of the global Diabetic Neuropathy Market will be provided in the report4. Insights from this report will allow marketers and management authorities of companies to make informed decisions with respect to their future product launch, technology upgrades, market expansion, and marketing tactics.

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/213

Further in the report, the Diabetic Neuropathy market is examined for Sales, Revenue, Price and Gross Margin. These points are analyzed for companies, types, and regions. In continuation with this data, the sale price is for various types, applications and regions are also included. The Diabetic Neuropathy industry consumption for major regions is given. Additionally, type wise and application wise figures are also provided in this report.

In this study, the years considered to estimate the market size of 2020-2026 Diabetic Neuropathy Market are as follows:History Year: 2015-2017Base Year: 2017Estimated Year: 2020Forecast Year 2020 to 2026

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Read more here:
Diabetic Neuropathy Market Global Status and Business Outlook 2018 to 2026 - Latest Herald

Read More...

Diabetic Peripheral Neuropathy Treatment Market Overview, Top Companies, Region, Application and Global Forecast by 2026 – Latest Herald

Tuesday, April 28th, 2020

The world is not only fighting a health pandemic but also an economic one, as the Novel Coronavirus (COVID 19) casts its long shadow over economies around the globe. The complete lockdown situation in several countries, has directly or indirectly impacted many industries causing a shift in activities like supply chain operations, vendor operations, product commercialization, etc. In the latest report on Diabetic Peripheral Neuropathy Treatment Market, published by Market Research Intellect, numerous aspects of the current market scenario have been taken into consideration and a concise analysis has been put together to bring you with a study that has Pre- and Post-COVID market analysis. Our analysts are watching closely, the growth and decline in each sector due to COVID 19, to offer you with quality services that you need for your businesses. The report encompasses comprehensive information pertaining to the driving factors, detailed competitive analysis about the key market entities and relevant insights regarding the lucrative opportunities that lie in front of the industry players to mitigate risks in such circumstances.

It offers detailed research and analysis of key aspects of the global Diabetic Peripheral Neuropathy Treatment market. The market analysts authoring this report has provided detailed information on growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Diabetic Peripheral Neuropathy Treatment market. Market participants can use the market analysis to plan effective growth strategies and prepare for future challenges in advance. Each trend in the global Diabetic Peripheral Neuropathy Treatment market is carefully analyzed and investigated by market analysts.

For Better Understanding, Download Sample PDF Copy of Diabetic Peripheral Neuropathy Treatment Market Research Report @ https://www.marketresearchintellect.com/download-sample/?rid=205689&utm_source=LHN&utm_medium=888

**Our SAMPLE COPY of the report gives a brief introduction of the Diabetic Peripheral Neuropathy Treatment market, Detailed TOC, key players of the market, list of tables and figures and comprising key countries regions.**

The Major Players in Global Diabetic Peripheral Neuropathy Treatment Market:

Global Diabetic Peripheral Neuropathy Treatment Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=205689&utm_source=LHN&utm_medium=888

Diabetic Peripheral Neuropathy Treatment Market Region Coverage (Regional Production, Demand & Forecast by Countries etc.):

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain etc.)

Asia-Pacific (China, India, Japan, Southeast Asia etc.)

South America (Brazil, Argentina etc.)

Middle East & Africa (Saudi Arabia, South Africa etc.)

Some Notable Report Offerings:

-> We will give you an assessment of the extent to which the market acquire commercial characteristics along with examples or instances of information that helps your assessment.

-> We will also support to identify standard/customary terms and conditions such as discounts, warranties, inspection, buyer financing, and acceptance for the Diabetic Peripheral Neuropathy Treatment industry.

-> We will further help you in finding any price ranges, pricing issues, and determination of price fluctuation of products in Diabetic Peripheral Neuropathy Treatment industry.

-> Furthermore, we will help you to identify any crucial trends to predict Diabetic Peripheral Neuropathy Treatment market growth rate up to 2026.

-> Lastly, the analyzed report will predict the general tendency for supply and demand in the Diabetic Peripheral Neuropathy Treatment market.

Have Any Query? Ask Our Expert@ https://www.marketresearchintellect.com/need-customization/?rid=205689&utm_source=LHN&utm_medium=888

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Diabetic Peripheral Neuropathy Treatment market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Diabetic Peripheral Neuropathy Treatment market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Diabetic Peripheral Neuropathy Treatment Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Diabetic Peripheral Neuropathy Treatment Market Size, Diabetic Peripheral Neuropathy Treatment Market Growth, Diabetic Peripheral Neuropathy Treatment Market Forecast, Diabetic Peripheral Neuropathy Treatment Market Analysis

Our Trending Reports

Dozers Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Drain Cleaning Machine Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Dried Botanicals Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read the original:
Diabetic Peripheral Neuropathy Treatment Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald

Read More...

Diabetic Neuropathy Drugs Market Overview, Top Companies, Region, Application and Global Forecast by 2026 – Latest Herald

Tuesday, April 28th, 2020

Astellas Pharma

Global Diabetic Neuropathy Drugs Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=175788&utm_source=LHN&utm_medium=888

Diabetic Neuropathy Drugs Market Region Coverage (Regional Production, Demand & Forecast by Countries etc.):

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain etc.)

Asia-Pacific (China, India, Japan, Southeast Asia etc.)

South America (Brazil, Argentina etc.)

Middle East & Africa (Saudi Arabia, South Africa etc.)

Some Notable Report Offerings:

-> We will give you an assessment of the extent to which the market acquire commercial characteristics along with examples or instances of information that helps your assessment.

-> We will also support to identify standard/customary terms and conditions such as discounts, warranties, inspection, buyer financing, and acceptance for the Diabetic Neuropathy Drugs industry.

-> We will further help you in finding any price ranges, pricing issues, and determination of price fluctuation of products in Diabetic Neuropathy Drugs industry.

-> Furthermore, we will help you to identify any crucial trends to predict Diabetic Neuropathy Drugs market growth rate up to 2026.

-> Lastly, the analyzed report will predict the general tendency for supply and demand in the Diabetic Neuropathy Drugs market.

Have Any Query? Ask Our Expert@ https://www.marketresearchintellect.com/need-customization/?rid=175788&utm_source=LHN&utm_medium=888

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Diabetic Neuropathy Drugs market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Diabetic Neuropathy Drugs market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Diabetic Neuropathy Drugs Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Diabetic Neuropathy Drugs Market Size, Diabetic Neuropathy Drugs Market Growth, Diabetic Neuropathy Drugs Market Forecast, Diabetic Neuropathy Drugs Market Analysis

Our Trending Reports

Sensors Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

U.S. Pest Control Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See the original post here:
Diabetic Neuropathy Drugs Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald

Read More...

Needing At-Home Workers, Call Centers Turn to People With Disabilities – The New York Times

Tuesday, April 28th, 2020

A workplace injury two decades ago when she was newly pregnant left Robin Irvin with neuropathy in her left leg and without a functioning bowel or bladder. She has been living on disability benefits since.

Now as the coronavirus pandemic upends the economy, Ms. Irvin, 48, has found a way to get back into the work force: She is answering customer service calls for a regional retail chain.

Call centers have had to adapt swiftly because the pandemic has dealt them a double blow. They are fielding more calls from customers inquiring about online orders or seeking refunds or forbearance. But many of the people who would normally answer those calls either cant get to work or are not equipped to work from home.

The transition has been messy; industry executives say they are struggling to ship computers, headsets and other equipment to employees. Many customer service representatives, who earned a median income of $34,710 last year, also dont have internet connections fast enough to take calls and log in to corporate computer systems. In addition, companies said, they have had to shut down offices in countries like the Philippines because of strict stay-at-home orders.

Some companies, like Charter Communications, the telecom giant known as Spectrum, have come under fire for requiring workers to go to offices. More than 230 Charter employees tested positive for Covid-19, and roughly half worked in offices or call centers, according to a person with knowledge of the company who was not authorized to speak publicly. A spokeswoman said a significant majority were now working from home.

Many employers are seeking new workers wherever they can find them. One option is hiring people with disabilities.

The National Telecommuting Institute, a nonprofit that works with the Social Security Administration to fill telecommuting jobs with people who have disabilities, has been approached by nearly a dozen additional companies seeking workers in the last three weeks. The institute has handled 30 percent more job postings over the past month than it did a year ago, and the numbers could be much higher in the next month, said Alan Hubbard, the institutes chief operating officer.

Founded in 1995, the telecommuting institute trains disabled people and helps them acquire the necessary equipment and broadband connections. The group also pairs beneficiaries with mentors who help them update their rsums, prepare for interviews and make the transition to work.

Were looking at this as tremendous opportunity to place people with disabilities into jobs, Mr. Hubbard said. Right now is the time companies can fulfill the promise to the Americans With Disabilities Act.

The institute is funded by government and business partnerships. Some companies outsource staffing, payroll and other human resource functions to the nonprofit.

Ms. Irvin, who lives in Sayre, Pa., found the telecommuting institute two years ago but didnt secure a job until March. She is now taking customer service calls for Meijer, a supermarket chain that operates in the Midwest and has worked with the institute since 2005.

I feel like I have some self-worth back, she said. Many of the calls she is fielding deal with online orders, which have spiked as people avoid shopping in stores.

Since the Covid-19 crisis, N.T.I. has helped us to meet additional customer demand, Meijer said in a statement. We have found they handle both basic and escalated customer emails and calls on Meijers behalf on par or better than their peers.

Call volumes are off the charts in several industries, including health care, insurance, technology and retail, said Michele Rowan, president of Customer Contact Strategies, a consulting company that specializes in remote work and call centers.

Alorica, an outsourcing company that handles calls for large corporations, has had to temporarily shut down outposts in Guatemala, the Dominican Republic and Jamaica. Shelter-in-place orders and curfews have prevented workers in those countries from going to work, and many cant work from home because they do not have computers and broadband internet connections.

The companys U.S. operation is having to pick up that slack, said Colleen Beers, the president of North American and European operations. The company is trying to hire 8,000 people to keep up with demand.

Call center work can be grueling, and some companies that employ lower-wage, lower-skilled workers have turnover rates of 30 percent to 45 percent. Some employers said the telecommuting institutes beneficiaries were less likely to quit.

Erin Blunt, the president of VForce, which handles membership renewal, emergency roadside services and other calls for AAA, said her company hired 95 percent of its employees through the institute. N.T.I. is hiring people who really, truly want to work, she said.

Benjamin Cargile, 43, landed a job with the bank PNC last month through the institute and hopes to keep it for years.

I dont really like being on disability, said Mr. Cargile, who lives in Morrisville, N.C., and has received disability benefits since 2013 because of agoraphobia and other mental health issues. You want to be able to support yourself.

Workers like Mr. Cargile and Ms. Irvin were ready to start working because they already had the equipment and internet connections that call centers expect. That wasnt true of many people who already had call center jobs, Ms. Rowan said.

Before the coronavirus, about 80 percent of call centers let some employees work from home at least some of the time, but only about 20 percent to 40 percent of workers did so, Ms. Rowan said. A survey of 108 call centers conducted by ContactBabel, a research firm, found that 71 percent of their workers in the United States were working remotely in mid-April.

Although call centers are considered essential businesses, many sent employees home because desks are typically spaced only three to four feet apart.

Alorica has sent 60 percent of its employees worldwide home to work. Of its 16,000 U.S. employees, 78 percent are home, Ms. Beers said. The transition was slow at first because the company had to coordinate with corporate customers to figure out what kind of equipment and internet access workers would need. In some cases, telecom companies couldnt get installers to homes fast enough to set up new connections.

We didnt have the opportunity for nine weeks to figure this out, Ms. Beers said.

Some companies were able to move faster. ASK, a smaller call center operator based in Montgomery, Ala., told its agents to do speed tests on their home internet connections on March 9 and now has 430 of its roughly 450 employees telecommuting, said Rick Burley, the companys president.

The rest either prefer to work in the office or dont have broadband at home. Mr. Burley said ASKs office, a former bowling alley, allows the few employees still coming in to sit 30 to several hundred feet apart.

Industry executives said they had noticed benefits from having employees work from home. For example, fewer employees are missing shifts, Ms. Beers said.

Ms. Rowan said employers could allow as many as half their workers to continue working from home once government officials lifted stay-at-home orders. That could provide more opportunities for people with disabilities, make it easier for employees to pick up extra hours and attract people who need part-time work.

It shouldnt have taken this to happen, frankly, Ms. Rowan said.

Tina Lewis, 48 started working for Live Response Solutions from her home in Portland, Ore., through the telecommuting institute in February. While it feels odd to benefit from the pandemic, said Ms. Lewis, who has fibromyalgia and peripheral neuropathy in her legs, she is grateful.

Having Social Security income thats OK. But youre barely surviving, she said. You need another way to survive, and being able to work from home makes that possible.

Read this article:
Needing At-Home Workers, Call Centers Turn to People With Disabilities - The New York Times

Read More...

In Las Vegas, A City Of Tourism And Leisure, The Economic Toll Has Been Devastating – Kaiser Health News

Tuesday, April 28th, 2020

In Las Vegas, one-third of the local economy depends on the leisure and hospitality industry, more than in any other major metropolitan area in the country. In other economic news, many Americans foresee their jobs coming back when pandemic tapers off, the outbreak exposes the wounds of the Great Recession, a political divide separates some essential workers and more.

The New York Times:How Las Vegas Became Ground Zero For The American Jobs CrisisWhen Valicia Anderson starts to count the people she knows in Las Vegas who have lost their jobs, she runs out of fingers fast. Her husband, the breadwinner of her family and a restaurant worker in the Rio casino. All 25 of his co-workers. Her grown son, in a temp agency. The technician who does her nails. The barber who cuts her husbands hair. Her best friend, a waitress. The three servers and a manager at the TGI Fridays that is her familys favorite treat. (Tavernise, 4/26)

The Associated Press:AP-NORC Poll: Most Losing Jobs To Virus Think Theyll ReturnOne out of every four American adults say someone in their household has lost a job to the coronavirus pandemic, but the vast majority expect those former jobs will return once the crisis passes, according to a new poll from The Associated Press-NORC Center for Public Affairs Research. The economic devastation writ by COVID-19 is clear: 26.4 million people have lost their job in the past five weeks, millions of homeowners are delaying mortgage payments and food banks are seeing lines of cars that stretch for miles. (Boak and Swanson, 4/24)

The Hill:Coronavirus Exposes Scars Of Great RecessionThe coronavirus and the desperate economic measures used to fight it are exposing some of the wounds inflicted during the Great Recession. While some Americans may be able to recover quickly when the pandemic subsides, the outbreak poses bigger threats to vulnerable communities that didnt benefit as much as others from the past 10 years of economic growth. (Lane, 4/26)

The New York Times:A Survey Of Essential Workers Shows A Political DivideDemocrats and Republicans differ on attitudes toward coronavirus risks and in workplace behaviors meant to reduce them, according to a new survey. This partisanship has the potential to hurt efforts to stop the spread of the virus. The data from Gallups Covid-19 tracking panel shows that people deemed essential workers are generating large numbers of close contacts with other people, putting themselves and those they live with at risk. Recognizing this, most workers have changed how they do their jobs to reduce the risk of viral transmission. (Rothwell, 4/27)

The New York Times:Risking My Life To Truck In Milk, Wine And Hand SanitizerJoseph Morales puts on a mask and gloves whenever he is delivering truckloads of wine, vodka and gin to a thirsty city. But he can do nothing about the person who coughs or comes too close in cramped stores. Im basically risking my life, said Mr. Morales, 41, a truck driver for a liquor distributor. If that person has it, Im doomed because Im right there. (Hu, 4/27)

The New York Times:Needing At-Home Workers, Call Centers Turn To People With DisabilitiesA workplace injury two decades ago when she was newly pregnant left Robin Irvin with neuropathy in her left leg and without a functioning bowel or bladder. She has been living on disability benefits since. Now as the coronavirus pandemic upends the economy, Ms. Irvin, 48, has found a way to get back into the work force: She is answering customer service calls for a regional retail chain. (Peiser, 4/26)

Read the original:
In Las Vegas, A City Of Tourism And Leisure, The Economic Toll Has Been Devastating - Kaiser Health News

Read More...

Pain Management Therapeutics Market Worldwide Survey On Product Need 2025 – Latest Herald

Tuesday, April 28th, 2020

Global Pain Management Therapeutics Market: Snapshot

Pain is invariably around whenever a body is suffering from diseases, which can be of multiple types including fibromyalgia, stomach ulcer, osteoarthritis, chronic arthritis, diabetic neuropathy, and cancer. Even during and after the therapy, pain constitutes a major part of the procedure that the subject has to bear but with technological advancements, it has become possible to considerably reduce the suffering and manage the pain via a variety of physiological mechanism, targeting the nociceptors for example. As the investments on robust infrastructure escalates across various emerging and developed countries, and awareness regarding the availability of alternatives increase, the demand in the global pain management therapeutics market is projected to increment at a healthy CAGR during the forecast period of 2017 to 2025.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1724

Currently, the developed regions of North America and Europe serve the maximum demand in the pain management therapeutics market, although highly populated emerging economies in Asia Pacific such as India and China are expected to turn into a profitable market towards the end of the forecast period.

In the current scenario, the global pain management therapeutics market is highly competitive, with the leading players constantly striving to come up with new products that are more efficient and hence gives them an edge over their competitors. In the current scenario, Purdue Pharma LP and Pfizer lead the market with nearly half the global shares, although the likes of Depomed Inc. and AstraZeneca Plc gaining ground. There is a strong presence of conventional medicines for pain management, which will keep the competitive landscape saturated throughout the forecast period. In the near future, a number of medium and small generic drugs manufacturers are expected to have a foray into pain management therapeutics market too, which will further intensity the tussle for the pole position.

Pain Management Therapeutics Market: Overview

Pain management therapeutics comprise various methods to ease varied degrees of pain among patients and improve their quality of life. Pharmaceutical therapeutics are usually the first line of treatment for pain management and if this does not work, patients opt for other methods such as pain managing devices, physiotherapy, and chiropractic therapy.

Pain management therapeutics can be categorized into antidepressants, anticonvulsants, opioids, anesthetics, antimigraine agents, non-steroidal anti-inflammatory drugs (NSAIDS), and non-narcotic analgesics. Various drugs are used for the management of different kinds of pain, such as fibromyalgia, neuropathic pain, arthritic pain, chronic back pain, post-operative pain, migraine, and cancer-related pain. A common trend that has been observed among patients is the consumption of over-the-counter (OTC) drugs rather than prescription drugs.

Pain Management Therapeutics Market: Trends

The growing prevalence of chronic diseases such as diabetes and cancer has been single-handedly driving the demand for pain management therapeutics and the number of people suffering from this kind of pain has been surging at a substantial rate. In addition to this, a massive geriatric population susceptible to arthritis, nerve damage, neuropathy, and joint pain is also boosting the market for pain management therapeutics. Supplementing market growth are favorable regulatory scenarios in many developed countries around the world.

However, as more and more patients opt for generic pain management drugs, the branded segment has been suffering a major setback. Moreover, the patent expiries of a number of blockbuster drugs will have a significant impact on the overall market for pain management therapeutics.

Pain Management Therapeutics Market: Market Potential

Despite the fact that leading brands are nearing a point of saturation, the pain management therapeutics market possesses strong potential for growth, particularly for smaller players. For instance, looking to expand its footprint in the global market as well as strengthen its U.S. pharmaceutical unit, Ireland-based Endo International plc acquired Auxilium Pharmaceuticals in 2015. The company also launched the BELBUCA Bucccal Film in 2016, which is used for the management of chronic pain.

Purdue Pharma, headquartered in Connecticut, U.S., ventured into a patent agreement with Acura Pharmaceuticals, Inc. and Egalet Corporation in 2016 for the development and sales of opioid pain management medicines.

Pain Management Therapeutics Market: Regional Outlook

Geographically, the global market for pain management therapeutics comprises North America, Europe, Latin America, Asia Pacific, and the Middle East and Africa. North America and Europe hold the largest share in the overall market and are slated to continue their dominance throughout the forecast period. The rising consumption of advanced pain management drugs and the availability of well-established and sophisticated healthcare infrastructure are the key factors driving the North America and Europe pain management therapeutics market. Asia Pacific is an immensely lucrative region and a number of players are looking to expand their operations in the many emerging countries in the region. This can be attributed to strong economic growth in nations such as China, India, Malaysia, and Japan, rising investments in the healthcare industry in these countries, and the increasing affordability of the population.

Pain Management Therapeutics Market: Competitive Analysis

There are a host of generic as well as branded drug manufacturers in the global pain management therapeutics market. These include GlaxoSmithKline plc, Novartis AG, Johnson & Johnson, Abbott Laboratories, AstraZeneca, Teva Pharmaceutical Industries Limited, Merck & Co., Inc., Purdue Pharma L.P., Endo Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, Depomed, Inc., and Pfizer, Inc. Although companies producing branded pain management therapeutics have a strong foothold in the market, the market is actually dominated by generic drug manufacturers, giving small- and medium-scale players immense scope for growth.

Read Comprehensive Overview of Report @https://www.tmrresearch.com/pain-management-therapeutics-market

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Read the original here:
Pain Management Therapeutics Market Worldwide Survey On Product Need 2025 - Latest Herald

Read More...

What Are The Qualifying Medical Conditions For Cannabis In Your State? – CBD Testers

Tuesday, April 28th, 2020

As of April 2020, there are 35 states that have legalizedmedicinal cannabis to some extent and of course, this varies greatly fromstate to state.

Despite the federal government keeping cannabis listed as a Schedule 1 narcotic, each state has the authority to create their own laws governing cannabis use within their borders. Most states allow the herb now, but the qualifying conditions that allow patients access to medical cannabis are different in each state. Use our guide to determine whether you qualify for medical cannabis in your home state.

*Recreational cannabis is legal in this state

Qualifying medical conditions for cannabis include:

Click here for the full list and for any updates http://www.akleg.gov/basis/Bill/Plaintext/21?Hsid=SB0094E

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions for cannabis include:

Any chronic or debilitating condition including but notlimited to: cachexia (wasting syndrome), chronic pain, recurring nausea,epilepsy, multiple sclerosis, and post-traumatic stress disorder.

Click here for the full list and for any updates http://www.azleg.gov/viewdocument/?docName=http://www.azleg.gov/ars/36/02801.htm

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions for cannabis include:

Any chronic or debilitating condition including but notlimited to: cachexia (wasting syndrome), chronic pain, recurring nausea,epilepsy, multiple sclerosis, and peripheral neuropathy.

Click here for the full list and for any updates http://www.healthy.arkansas.gov/Pages/MedMarijuana.aspx

**Recreational cannabis is legal in this state

Qualifying medical conditions for cannabis include:

Any other chronic or persistent medical symptom that considerablylimits a persons abilities or diminishes their quality of life, as defined bythe Americans with Disabilities Act of 1990.

Click here for the full list and for any updates https://leginfo.legislature.ca.gov/faces/codes_displayText.xhtml?lawCode=HSC&division=10.&title=&part=&chapter=6.&article=2.5.

*Recreational cannabis is legal in this state

Qualifying medical conditions for cannabis include:

Any chronic or debilitating condition including but notlimited to: cachexia (wasting syndrome), persistent muscle spasms, seizures, severenausea, and severe pain, as well as any condition that is approved by a doctor.

Click here for the full list and for any updates https://www.colorado.gov/pacific/cdphe/qualifying-medical-conditions-medical-marijuana-registry

*Recreational cannabis is NOT legal in this state (although this will be up for a vote soon)

Qualifying medical conditions for cannabis include:

For underagepatients:

Click here for the full list and for any updates http://www.ct.gov/dcp/cwp/view.asp?q=509628&dcpNav=%7C

*Recreational cannabis is NOT legal in this state (although this will be up for a vote soon)

Qualifying medical conditions for cannabis include:

Any chronic or debilitating conditions including but notlimited to: cachexia (wasting syndrome), severe pain that has not responded toprescribed medication in 3 months, recurring nausea, muscle spasms, andmultiple sclerosis.

Click here for the full list and for any updates http://dhss.delaware.gov/dph/hsp/medmarpt.html

*Recreational cannabis is legal in this district

Qualifying medical conditions include:

Any other condition that is chronic, that could benefit frommedical cannabis (as determined on a case-by-case basis) and cannot beeffectively treated by standard medical practices.

Click here for the full list and for any updates: http://doh.dc.gov/sites/default/files/dc/sites/doh/publication/attachments/140523MMPRegulationsRevised.pdf

*Recreational cannabis is not legal in this state

Qualifying medical conditions for cannabis include:

Click here for the full list and for any updates http://www.leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&Search_String=&URL=0300-0399/0381/Sections/0381.986.html

*Recreational cannabis is not legal in this state

Qualifying medical conditions for cannabis include:

Any chronic or debilitating condition including but not limitedto: cachexia (wasting syndrome), severe pain, severe nausea, seizures, musclespasms, multiple sclerosis, and Crohns disease.

Click here to read the full list and for any updates http://health.hawaii.gov/medicalcannabisregistry/providers/debilitating-medical-conditions/

*Recreational cannabis is legal in this state

Qualifying medical conditions include:

Click here forthe full list and for any updates http://www.dph.illinois.gov/topics-services/prevention-wellness/medical-cannabis/debilitating-conditions

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Click here for a full list and for any updates list of guidelines http://www.state.ia.us/odcp/docs/CBDFinalFactSheetIowaJune2014.pdf

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Click here for a full list or for any updates http://ldh.la.gov/index.cfm/page/3633

*Recreational cannabis is legal in this state

Qualifying medical conditions include:

Sec. 19. 22 MRSA2423-B

Click here for afull list or for any updates https://legislature.maine.gov/legis/bills/bills_128th/billtexts/HP106001.asp

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Click here for the full list and for any updates http://mmcc.maryland.gov/Pages/patients.aspx

*Recreational cannabis is legal in this state

Qualifying medical conditions include:

Any other debilitating condition as determined by a qualified physician.

Clickhere for the full list and for any updates https://malegislature.gov/Laws/SessionLaws/Acts/2012/Chapter369

*Recreational cannabis is legal in this state

Qualifying medical conditions include:

A chronic ordebilitating including but not limited to: cachexia (wasting disease), severeand chronic pain, severe nausea, seizures, muscle spasms, and multiplesclerosis.

Click here for thefull list or for any updates http://www.legislature.mi.gov/(S(vxeekwsfu2lon4z4ssftgnjt))/mileg.aspx?page=getObject&objectName=mcl-333-26423

*Recreational cannabis is not legal in this state

Qualifying medical conditions include:

Any other medical condition thats approved by the medicalcommissioner

Click here for the full list or for any updates http://www.health.state.mn.us/topics/cannabis/patients/conditions.html

*Recreational cannabis is not legal in this state

Qualifying medical conditions include:

Any other chronicor debilitating medical condition that can benefits from the use of medicalcannabis, as determined by a qualified physician.

Click here forthe full list or for any updates https://health.mo.gov/safety/medical-marijuana/faqs.php

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Click here forthe full list or for any updates http://dphhs.mt.gov/marijuana/mmpfaq#159692088-what-are-the-debilitating-conditions-for-which-i-can-recommend-marijuana-for-my-patients

*Recreational cannabis is legal in this state

Qualifying medical conditions include:

Any other chronic or debilitating medical condition that canbenefit from the use of medical cannabis, as determined by a qualifiedphysician.

Click here for the full list or for any updates http://dpbh.nv.gov/Reg/MM-Patient-Cardholder-Registry/dta/FAQs/Medical_Marijuana_Patient_Cardholder_Registry_-_FAQs/

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Any other chronic or debilitating medical condition that canbenefit from the use of medical cannabis, as determined by a qualifiedphysician.

Click here for the full list or for any updates https://www.dhhs.nh.gov/oos/tcp/medical-conditions.htm

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Any chronic or debilitating condition including but notlimited to: cachexia (wasting syndrome), chronic pain, recurring nausea,epilepsy, multiple sclerosis, and peripheral neuropathy.

Click here for the full list and for any updates http://nj.gov/health/medicalmarijuana/pat_faqs.shtml#7

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Any other chronic or debilitating medical condition that canbenefit from the use of medical cannabis, as determined by a qualifiedphysician.

Click here for the full list or for any updates https://nmhealth.org/publication/view/form/135/

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Any other chronic or debilitating medical condition that canbenefit from the use of medical cannabis, as determined by a qualifiedphysician.

Click here for the full list or for any updates http://www.health.ny.gov/regulations/medical_marijuana/faq.htm

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Any other chronic or debilitating medical condition that canbenefit from the use of medical cannabis, as determined by a qualifiedphysician.

Click here for the full list or for any updates https://www.legis.nd.gov/assembly/65-2017/documents/17-0630-05000.pdf

*Recreational cannabis is NOT legal in this state

The rest is here:
What Are The Qualifying Medical Conditions For Cannabis In Your State? - CBD Testers

Read More...

Optic Neuropathy Market by Top Manufacturers with Production, Price, Revenue (value) and Market Share to 2026 – Latest Herald

Tuesday, April 28th, 2020

Optic Neuropathy Pipeline Review, H1 2019>This report offers a detailed view of market opportunity by end user segments, product segments, sales channels, key countries, and import / export dynamics. It details market size & forecast, growth drivers, emerging trends, market opportunities, and investment risks in over various segments in Optic Neuropathy industry. It provides a comprehensive understanding of Optic Neuropathy market dynamics in both value and volume terms.

The key players covered in this study > Allergan Plc, Antoxis Ltd, Quark Pharmaceuticals Inc, Recursion Pharmaceuticals Inc, Regenera Pharma Ltd, Regeneron Pharmaceuticals Inc

The final report will add the analysis of the Impact of Covid-19 in this report Optic Neuropathy industry.

Get Sample Copy of the Complete Report

This report focuses on the global Optic Neuropathy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Optic Neuropathy development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

Table Of Content

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 North America

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

This report studies the Optic Neuropathy market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Optic Neuropathy market by product type and applications/end industries.

Customization of this Report: This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. For more relevant reports visitwww.reportsandmarkets.com

What to Expect From This Report on Optic Neuropathy Market:

The developmental plans for your business based on the value of the cost of the production and value of the products, and more for the coming years.

A detailed overview of regional distributions of popular products in the Optic Neuropathy Market.

How do the major companies and mid-level manufacturers make a profit within the Optic Neuropathy Market?

Estimate the break-in for new players to enter the Optic Neuropathy Market.

Comprehensive research on the overall expansion within the Optic Neuropathy Market for deciding the product launch and asset developments.

If U Know More about This Report

Any special requirements about this report, please let us know and we can provide custom report.

About Us:

Market research is the new buzzword in the market, which helps in understanding the market potential of any product in the market. Reports And Markets is not just another company in this domain but is a part of a veteran group called Algoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world.

For more detailed information please contact us at:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

More here:
Optic Neuropathy Market by Top Manufacturers with Production, Price, Revenue (value) and Market Share to 2026 - Latest Herald

Read More...

Page 4«..3456..1020..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick